Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid

ABSTRACT

Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions.

1. RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application Ser.No. 61/141,856, filed Dec. 31, 2008, entitled “METHOD OF PREPARINGVORELOXIN.” The disclosure of the above referenced application isincorporated by reference herein in its entirety.

2. FIELD

Provided herein are methods for preparing(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthrydine-3-carboxylicacid, methods for preparing intermediates useful in the preparation ofthe compound, compositions comprising the compound, methods of use ofsuch compositions for treatment of cancer and methods of using theintermediates in preparing(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid.

3. BACKGROUND

The compound(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, having the structure:

is also known as SNS-595 or AG-7352. The United States Adopted NamesCouncil (USANC) has assigned the name “Voreloxin” to this compound.

SNS-595 is known for its anti-tumor activity (see. Tsuzuki et al., J.Med. Chem., 47:2097-2106, 2004 and Tomita et al., J. Med. Chem.,45:5564-5575, 2002). Treatment of various cancers with SNS-595 has beenproposed in the literature, and has shown preclinical activity againstvarious cancer cell lines and xenografts. Various dosing regimens forthe use of this compound have been reported. For example, see U.S.Patent Application Pub. Nos. 2005-0203120 A1; 2005-0215583 A1 and2006-0025437 A1, all of which arc incorporated herein by reference intheir entireties. SNS-595 is presently being tested in clinical trialsto assess safety and efficacy in human cancer patients, and hasdemonstrated clinical activity against acute myeloid leukemia andovarian cancer.

SNS-595 can be prepared using techniques known to one of skill in theart. See, for example, U.S. Pat. No. 5,817,669, issued Oct. 6, 1998,Japanese Patent Application No. Hei 10-173986, published Jun. 26, 1998,WO 2007/146335, Tsuzuki et al., J. Med. Chem., 47:2097-2106, 2004 andTomita et al., J. Med Chem., 45: 5564-5375, 2002, which are incorporatedherein by reference in their entirety.

Conventional methods of preparing SNS-595 can yield compositionscomprising other compounds that either result from side reactions thatoccur during the SNS-595 synthesis process or are reagents that remainunreacted.

International patent application WO 2007/146335, published Dec. 21,2007, describes preparation of a composition that comprises SNS-595 and(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthridine-3-carboxylicacid, which is described therein as an “N-desmethyl” compound. Data arepresented indicating that the N-desmethyl compound is shown to be activein a cytotoxicity assay. The N-desmethyl compound is a significant sideproduct of the conventional approach, to synthesizing SNS-595.

Thus, there remains a need for improved methods for preparing SNS-595substantially free of contaminants, to provide the compound in asubstantially pure form well suited for formulation into pharmaceuticalcompositions for the treatment of cancer without the need for laboriouspurification steps.

4. SUMMARY

Although certain by-products are known to exist in SNS-595 preparation,reducing the amount of such in the final drug product is important.Since cancer patients undergo significant chemotherapy and radiation andcan often have compromised immune systems, it is beneficial to deliverhighly pore drug to cancer patients. Further, for parenteraladministration, the purity and percentage of the drug delivered isextremely important because the drug enters directly into the bloodstream. As a result, described herein are processes that can yieldsubstantially pure SNS-595. In addition, the processes provided can bescaled up to commercial manufacturing of snhstantialjy pure SNS-595.

In one embodiment, provided herein is a process for preparingintermediates required in the preparation of SNS-595.

In certain embodiments, provided herein are processes for preparation ofSNS-595. In certain embodiments, the processes provided herein yieldcompositions comprising SNS-595 and N-desmethyl-SNS-595. In oneembodiment, provided herein is a process for preparing intermediatesuseful in the preparation of SNS-595.

In one embodiment, provided herein is a process for preparing SNS-595 asillustrated in Schemes 1 and 2.

In this route, Compound 4 is obtained by nucleophilic opening of epoxide(Compound 3) by methylamine, thereby eliminating the impuritiesresulting from incomplete methylation. In certain, embodiments. Compound2 is directly converted to Compound 4 by treatment with methylamine anda base, such as sodium bicarbonate. Compound 4 is resolved, by reactionwith a chiral acid, such as L-(−)-malic acid or L-(−)-pyroglutamic acidto form a chiral salt.

Compound 8, prepared according to Scheme 1 or otherwise, is then reactedwith7-chloro-4-oxo-1-thiazol-2-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylicacid ethyl ester to obtain SNS-595 as illustrated in Scheme 2.

In certain embodiments, processes provided herein yield compositionscomprising at least about 99.5% SNS-595 and less than about 0.5% ofimpurity by total weight of the composition, wherein the percentage isbased upon total weight of the composition. In certain embodiments, thecompositions comprise at least about 99.5% SNS-595 and less than about0.5% N-desmethyl-SNS-595 by total weight of the composition, whereineach of the percentage is based upon total weight of the composition. Incertain embodiments, the compositions comprise at least about 99.5%SNS-595 and less than about 0.5% O-desmethyl-SNS-595 by total weight ofthe composition, wherein each of the percentage is based upon totalweight of the composition. In certain embodiments, the compositionscomprise at least about 99.5% SNS-595 and less than about 0.5% totalO-desmethyl-SNS-595 and N-desmethyl-SNS-595 by total weight of thecomposition, wherein each of the percentage is based upon total weightof the composition. In certain embodiments, the compositions comprise atleast about 99.5% SNS-595 and less than about 0.5%N,O-bisdesmethyl-SNS-595 by total weight of the composition, whereineach of the percentage is based upon total weight of the composition. Incertain embodiments, the compositions comprise at least about 99.5%SNS-595 and less than about 0.5% total O-desmethyl-SNS-595,N-desmethyl-SNS-595 and N,O-bisdesmethyl-SNS-595 by total weight of thecomposition, wherein each of the percentage is based upon total weightof the composition.

In certain embodiments, provided herein is a scale-up process forpreparing substantially pure SNS-595.

In certain embodiments, the compositions are useful in the methods oftreating, preventing or managing one or more cancers in a human or othersubject.

In certain embodiments, provided herein are pharmaceutical compositionscomposing substantially pure SNS-595 for treatment of cancer. The typesof cancers that can be treated, prevented, or managed using methodsprovided herein include, but are not limited to solid tumors andblood-borne tumors.

Also provided are methods of preparing the compositions and compoundsdescribed herein. In certain embodiments provided herein, areintermediates useful in preparing SNS-595.

5. DETAILED DESCRIPTION

5.1 Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as is commonly understood by one of ordinary skidin the art. All patents, applications, published applications and otherpublications are incorporated by reference in their entirety. In theevent that there is a plurality of definitions for a term herein, thosein this section prevail unless stated otherwise.

As used herein, “protecting group” is any of the well recognizedprotecting groups for active groups in a molecule. In processesdescribed herein the free groups include, hydroxyl, amino and carboxy.Exemplary protecting groups include, but are not limited to,benzyloxycarbonyl, t-butoxycarbonyl, and the like. As used herein,“protection reaction” refers to a reaction in which an active group isblocked with a protecting group to avoid undesired reactions with theactive group. As used herein, “protecting” refers to blocking an activegroup on a compound with protecting group to avoid undesired reactionswith the active group. As used herein, “deprotection reaction” refers toa reaction in which the protecting group is removed to regenerate theactive group. As used herein, “deprotecting” refers removing aprotecting group on a compound to regenerate the active group. Forexample, t-butoxycarbonyl protecting group can be removed from an aminogroup by reaction with deprotecting reagents such as HCl/MeOH,trimethylsilane or p-toluene sulfonic acid monohydrate.

As used heroin, “epoxide opening” refers to a reaction in which anepoxide ring is opened with, a nucleophile, such as a primary amine, forexample methylamine, to yield a compound containing a free hydroxylgroup.

As used herein, “methylation” refers to a reaction in which a freehydroxyl or amine group undergoes a reaction with a methylating agentwherein a hydrogen is replaced by a methyl group. The methylationreaction can be accomplished with, for example, dimethyl sulfate.

As used herein, “methylating” refers to replacing a hydrogen in ahydroxyl or an amine group by a methyl group through a reaction with amethyiating agent. The methylation reaction can be accomplished with,for example, dimethyl sulfate.

As used herein “resolution” or “chiral resolution” refers to a processfor the separation of racemic compounds into their enantiomers.

As used herein “resolving” refers to separating a racemic compound intoits enantiomers.

As used herein “commercial scale” or “process scale” refers to a processfor SNS-595 that yields greater than 1 kilogram of SNS-59S.

As used herein, “impurity” refers to chemical species other than(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiaxolyl)-1,8-naphthyridine-3-carboxylicacid.

As used herein, “SNS-595” means(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-methylamino-1-prryolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthrydine-3-carboxylicacid, as well as any ionic form, salts, solvates, e.g., hydrate, orother forms of that compound, including mixtures thereof. Thus,compositions comprising SNS-595 may include(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid or an ionic form thereof, salt, solvate, e.g., hydrate, or otherform of the compound. In some embodiments, SNS-595 is provided as apharmaceutically acceptable salt.

As used herein, “SNS-595 Substance” means a composition consistingessentially of(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, including less than 0.5% (by mass) of any other individualcompound or impurity based on total weight of the composition. In someembodiments, the chemical process provided herein permits kilogram scalesynthesis of SNS-595 Substance that includes less than 0.3%, less than0.2%, less than 0.1%, or less than 0.05%1,4-dihydro-7-[3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, wherein each of the percentage is based upon total weight of thecomposition. In some embodiments, the chemical process provided hereinpermits kilogram scale synthesis of SNS-595 Substance that includes lessthan 0.3%, less than 0.2%, less than 0.1%, or less than 0.05%1,4-dihydro-7-[(3S,4S)-3-oxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, wherein each of the percentage is based upon total weight of thecomposition. In some embodiments, the chemical process provided hereinpermits kilogram scale synthesis of SNS-595 Substance that includes lessthan 0.3%, less than 0.2%, less than 0.1%, or less than 0.05%1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiaxolyl)-1,8-naphthyridine-3-carboxylicacid and1,4-dihydro-7-[(3S,4S)-3-oxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthridine-3-carboxylicacid, wherein each of the percentage is based upon total weight of thecomposition.

As used herein, “SNS-595 Active ingredient” or “SNS-595 API (ActivePharmaceutical Ingredient)” means a composition comprising(+)-1,4-diihydro-7-[(3S,4S)-3-methoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and less than 0.1%1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and/or1,4-dihydro-7-[(3S,4S)-3-oxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, where the percentage is based on the total weight of thecomposition.

As used herein, “N-desmethyl-SNS-595” refers to(+)-4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and has the following chemical structure:

“O-desmethyl-SNS-595” refers to(+)-1,4-dihydro-7-[(3S,4S)-3-hydxoxy-4-methylamino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and has the following chemical structure:

“N,O-bisdesmethyl-SNS-595” refers to(+)-1,4-dihydro-7-[(3S,4S)-3-hydroxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and has the following chemical structure:

As used herein, “SNS-593 Product” means an aqueous composition ofSNS-595 comprising about 10 mg/mL SNS-595 API, about 45 mg/mLD-sorbitol, and an organic acid, prepared in water, in which the pH ofthe composition, is about 2.3-2.7. In some embodiments, the organic acidis methanestdfonic acid. In some embodiments, the pH of the SNS-595Product is about 2.5. In some embodiments, the SNS-595 Product issterile,

As used herein, “composition” refers to a composition of SNS-595 andimpurities having a thiazolyl-oxo-naphthyridine-3-carboxylic acidscaffold. Such impurities include N-desmethyl-SNS-595,O-desmethyl-SNS-595 and N,O-bisdesmethyl-SNS-595.

As used herein, the term “substantially pure” with, respect to SNS-595refers to a composition that includes at least about 99.5%, 99.6%,99.7%, 99.8%, 99.9% or up to about 100% by weight of SNS-595, theremainder comprising other chemical species. The purity of SNS-595provided herein can be determined by standard methods of analysis, suchas high performance liquid chromatography (HPLC), used by those of skillin the art to assess such purity. In certain embodiments, SNS-595 issufficiently pure such that further purification would not deteeiabiyalter the physical and chemical properties, such as biological activity,of the compound.

As used herein, “enantiomerically pure SNS-595” refers to SNS-595 thatis substantially free from(−)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiozolyl)-1,8-naphthyridine-3-carboxylic acid(i.e., in enantiomeric excess). In other words, SNS-595 is substantiallyfree from(−)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazoyl)-1,8-naphthrydine-3-carboxylicacid, and is, thus, in enantiomeric excess of the “(−)” form. The term“enantiomerically pure” or “pure enantiomer” denotes that the compoundcomprises more than about 95%, 96%, 97%, 98%, 99%, 99.5, 99.6%, 99.7%,99.8%, or 99.9% by weight of(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthrydine-3-carboxylicacid.

As used, herein, and unless otherwise indicated, the terms “treat,”“treating” and “treatment” refer to alleviating or reducing the severityof a disease or a symptom, associated with the disease or conditionbeing treated.

As used herein, “prevent”, “prevention.” and other forms of the wordinclude the inhibition, of onset or progression of a disease or disorderor a symptom, of the particular disease or disorder. In someembodiments, patients with familial history of cancer are candidates torpreventive regimens. Generally, in the context of cancer, the term“preventing” refers, to administration of the drug prior to the onset ofsigns or symptoms of a cancer, particularly in patients at risk ofcancer.

As used herein, and unless otherwise indicated, the term “managing”encompasses preventing the recurrence of the particular disease ordisorder in a patient who had suffered from it, lengthening the time apatient who had suffered from the disease or disorder remains inremission, reducing mortality rates of the patients, and/or maintaininga reduction in severity or avoidance of a symptom associated with thedisease or condition being managed.

As used herein, “subject” means an animal, typically a mammal, includinga human being. As used herein, “patient” means a human subject.

As used herein, the term “cancer” includes, but is not limited to, solidtumors and blood-home tumors. In some embodiments, the cancer may be acarcinoma or a sarcoma. In certain embodiments, the cancer is ahematologic malignancy, such as a leukemia, lymphoma (e.g.,non-Hodgkin's lymphoma, Hodgkin's lymphoma), or a myeloma. In certainembodiments, the leukemia is chronic lymphocytic leukemia, chronicmyeloid leukemia, acute lymphocytic leukemia, acute myelogenous,leukemia and acute myeloblastlc leukemia. In certain embodiments, thecancer comprises solid tumor. In certain embodiments, the cancer is abladder cancer, brain cancer (e.g., astrocytoma, glioma, meningioma,neuroblastoma, or others), bone cancer (e.g., osteosarcoma), breastcancer, cervical cancer, cholangiocarcinoma, digestive tract cancer(e.g., oral, esophageal, stomach, colon or rectal cancer), head and neckcancer, leiomyosarcoma, liposarcoma, liver cancer, long cancer (smallcell or non-small cell), melanoma, mesothelioma, myeloma, nasopharyngealcancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer,prostate cancer, renal cancer, rhabdomyosarcoma, salivary gland cancer,skin cancer, spindle cell carcinoma, testicular cancer, thyroid cancer,or uterine cancer (e.g., endometrial cancer). In certain, embodiments,the cancer can he relapsed following a previous therapy, or refractoryto conventional therapy. In certain embodiments, the cancer can bedisseminated or metastatic.

As used, herein, the term “precancerous condition” means a condition,abnormal tissue growth, or lesion that tends or is likely to becomecancerous. Precancerous conditions include, for example, actinickeratosis, adenomatous polyps of the colon, cervical dysplasia, andantecedent hematological disorders such as myelofibrosis, aplasticanemia, paroxysmal nocturnal hemoglobinuria, polycythemia vera, andmyelodysplastic syndrome,

As used herein, the term “relapse” means a return of cancer signs orsymptoms in a subject who has bad a previous improvement or remission ofcancer as a result of cancer therapy.

As used herein, the term, “refractory” means that the cancer is orbecomes resistant to a cancer therapy.

As used, herein, and unless otherwise specified, the terms“therapeutically effective amount” and “effective amount” of a compoundrefer to an amount sufficient to provide a therapeutic benefit in thetreatment, prevention and/or management of a disease, to delay orminimise one or more symptoms associated with the disease or disorder tobe treated. The terms “therapeutically effective amount” and “effectiveamount” can encompass an amount that improves overall therapy, reducesor avoids symptoms or causes of disease or disorder or enhances thetherapeutic efficacy of another therapeutic agent.

As used herein and unless otherwise indicated, the term“pharmaceutically acceptable salt” includes, but is not limited to, asalt of an acidic or basic group that can be present in the compoundsprovided herein. Under certain acidic conditions, the compound can forma wide variety of salts with various inorganic and organic acids. Theacids that can be used to prepare phannaceutically acceptable salts ofsuch basic compounds are those that form salts comprisingpharmacologically acceptable anions including, but not limited to,acetate, benzenesulfonate, benaoate, bicarbonate, bitartrate, bromide,calcium edetate, carnsylate, carbonate, chloride, bromide, iodide,citrate, dihydrochloride, edetate, edisylate, estolate, esylate,fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate,hexylresorcinate, hydrabamine, hydroxynaphthoate, isethionate, lactate,lactobionate, malate, maleate, mandelate, methanesolfonate (mesylate),methylsulfate, muscate, napsylate, nitrate, pantothenate,phosphate/diphosphate, polygalacturonate, salicylate, stearate,succinate, sulfate, tannate, tartrate, teoclate, triethiodide, andparnoate. Under certain basic conditions, the compound can form basesalts with various pharmacologically acceptable cations. Non-limitingexamples of such salts include alkali metal or alkaline earth metalsalts and, particularly, calcium, magnesium, sodium, lithium, zinc,potassium and iron salts.

As used herein and unless otherwise indicated, the term “hydrate” meansSNS-595 or a salt thereof further including a stoichiometric ornon-stoicehiometric amount of water bound by non-covalent intermolecularforces. The hydrates of SNS-595 can be crystalline or non-crystalline.

As used herein and unless otherwise indicated, the term “solvate” meansa solvate formed from the association of one or more solvent moleculesto a compound provided herein. The term “solvate” includes hydrates(e.g., monohydrate, dihydrate, trihydrate, tetrahydrate, and the like).The solvates of SNS-595 can be crystalline or non-crystalline.

As used herein, the transitional phrase “consisting essentially of”limits the scope of a claim to the specified materials and those that donot materially affect the basic and novel characteristic(s) of theclaimed subject matter.

The terms “co-administration” and “in combination with” include theadministration of two therapeutic agents (for example, SNS-595 or acomposition provided herein and another anti-cancer agent or secondagent) either simultaneously, concurrently or sequentially with nospecific time limits. In one embodiment, both agents are present in thecell or in the patient's body at the same time or exert their biologicalor therapeutic effect at the same time. In one embodiment, the twotherapeutic agents are in the same composition or unit dosage form. Inanother embodiment, the two therapeutic agents are in separatecompositions or unit dosage forms.

The term “supportive care agent” refers to any substance that treats,prevents, manages, reduces, or avoids an adverse or unwanted effect ofSNS-595 treatment.

5.2 Compounds and Compositions

In certain embodiments, provided herein are processes for preparation ofSNS-595. In certain embodiments, the processes provided herein yieldSNS-595 Substance. In certain embodiments, the processes provided hereinyield compositions comprising SNS-595, N-desmethyl-SNS-595 andO-desmethyl-SNS-595. In certain embodiments, the processes providedherein yield compositions comprising substantially pure SNS-595. Incertain embodiments, the processes provided herein yield compositionsconsisting essentially of SNS-595, N-desmethyl-SNS-595 andO-desmethyl-SNS-595. In certain embodiments, the processes providedherein yield compositions comprising SNS-595 and N-desmethyl-SNS-595. Incertain embodiments, the processes provided herein, yield compositionsconsisting essentially of SNS-595 and N-desmethyl-SNS-595. In certainembodiments, the processes provided herein yield compositions comprisingSNS-595 and O-desmethyl-SNS-595. In certain embodiments, the processesprovided herein yield compositions consisting essentially of SNS-595 andO-desmethyl-SNS-595. In certain embodiments, the processes providedherein yield compositions comprising SNS-595 andN,O-bisdesmetbyl-SNS-595. In certain embodiments, the processes providedherein yield compositions consisting essentially of SNS-595 andN,O-bisdesmethyl-SNS-595. In certain embodiments, the processes providedherein yield compositions consisting essentially of SNS-595,N-desmethyl-SNS-595; O-desmethyl-SNS-595 and N,O-bisdesmethyl-SNS-595.

In certain embodiments, the compositions provided herein consistessentially of at least about 99.5% SNS-595 and less than about 0.5% ofimpurity by total weight of the composition, wherein each of thepercentages is based upon total weight of the composition. In certainembodiments, the compositions provided herein consist essentially of atleast about 99.5% SNS-595 and less than about 0.5% N-desmethyl-SNS-595by total weight of the composition, wherein each of the percentages isbased upon total weight of the composition. In one embodiment, providedherein is a composition consisting essentially of at least 99.9% SNS-595and less than about 0.1% N-desmethyl-SNS-595. In one embodiment,provided herein is a composition consisting essentially of at least99.95% SNS-595 and less than about 0.05% N-desmethyl-SNS-595. In oneembodiment, the composition consists essentially of at least about99.96%, at least about 99.97%, at least about 99.98%, at least about99.99% SNS-595 by weight of the composition. In certain embodiments, thepercentages of SNS-595 and N-desmethyl-SNS-595 in the composition arebased upon total weight of the two components.

In certain embodiments, provided herein is a composition consistingessentially of SNS-595 and less than about 0.05% by weight ofN-desmethyl-SNS-595. In one embodiment, the composition consistsessentially of SNS-595 and less than about 0.01%, 0.02%, 0.03%, 0,04% or0.05% of N-demethyl-SNS-595 based upon total weight of the composition.

In certain embodiments, the compositions provided herein consistessentially of at least about 99.5% SNS-595 and less than about 0.5%O-desmethyl-SNS-595 by total weight of the composition, wherein each ofthe percentages is based upon total weight of the composition. In oneembodiment, provided herein is a composition consisting essentially ofat least about 99.9% SNS-595 and less than about 0.1%O-desmethyl-SNS-595. In one embodiment, provided herein is a compositionconsisting essentially of at least about 99.95% SNS-595 and less thanabout 0.05% O-desmethyl-SNS-595. In one embodiment, the compositionconsists essentially of at least about 99.96%, at least about 99.97%, atleast about 99.98%, at least, about 99.99% SNS-595 by weight of thecomposition. In certain embodiments, the percentages of SNS-595 andO-desmethyl-SNS-595 in the composition are based upon total weight ofthe two components.

In certain embodiments, provided herein is a composition comprisingessentially of SNS-595 and less than about 0.05% by weight ofO-desmethyl-SNS-595. In one embodiment, the composition consistsessentially of SNS-595 and less than about 0.01%, 0.02%, 0.03%, 0.04% or0.05% of O-desmethyl-SNS-595 based upon total weight of the composition.

In certain embodiments, the compositions provided herein consistessentially of SNS-595 and less than about 0.5%, 0.3%, 0.1%. 0.05%,0.03% or 0.01% total N-desmethyl-SNS-595 and O-desmethyl-SNS-595 bytotal weight of the composition, wherein each of the percentages isbased upon total weight of the composition.

In certain embodiments, the compositions consist essentially of at leastabout 99.5% SNS-595 and less than about 0.5%, 0.3%, 0.1%, 0.05%, 0.03%or 0.01% N,O-bisdesmethyl-SNS-595 by total weight of the composition,wherein each of the percentage is based upon total weight of thecomposition. In certain embodiments, the percentages of SNS-595 andN,O-bisdesmethyl-SNS-595 in the composition are based upon total weightof the two components.

In certain embodiments, the compositions provided herein consistessentially of SNS-595 and less than about 0.5%, 0.3%, 0.1%, 0.05%,0.03% or 0.01% total N-desmethyl-SNS-595, O-desmethyl-SNS-595 andN,O-bisdesmethyl-SNS-595 by total weight of the composition, whereineach of the percentages is based upon total weight of the composition.In certain embodiments, the percentages of SNS-595, N-desmethyl-SNS-595,O-desmethyl-SNS-595 and N,O-bisdesmetbyl-SNS-595 in the composition arebased upon total weight of the four components.

In certain embodiments, SNS-595 substance provided herein can besynthesized on a process scale.

In certain embodiments, SNS-595 Substance provided herein is useful inthe methods of treating, preventing or managing one or more cancers in asubject.

In one embodiment, provided herein are methods of treatment, prevention,or amelioration of one or more cancers comprising administering SNS-595Substance.

Also provided herein are compounds of formula 5A and 5B and methods ofpreparing the compounds.

In certain embodiments. Compound 5 A, and Compound 5B are useful asintermediates in synthesis of SNS-595.

5.3 Methods of Preparation

SNS-595 can be prepared from(3S,4S)-4-methoxy-N-methylpyrrolidin-3-amine•2TsOH and7-chloro-4-oxo-1-thiazol-2-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylicacid ethyl ester as described in Example 3.

In one embodiment, the chemical process for preparation of SNS-595provided herein yields SNS-595 Substance consisting essentially of atleast about 99.5% SNS-595, including less than about 0.5% of impurity.In another embodiment, the chemical process yields SNS-595 Substanceconsisting essentially of at least about 99.7% SNS-595, including about0.3% of impurity, at least about 99.9% SNS-595 and less than about 0.1%of impurity, at least about 99.95% SNS-595 and less than about 0.05% ofimpurity, at least about 99.97% SNS-595 and less than about 0.03% ofimpurity, at least about 99.98% SNS-595 and less than about 0.02% ofImpurity or at least about 99.99% SNS-595 and less than about 0.01% ofimpurity.

In certain embodiments, the process provided herein yields SNS-595Substance consisting essentially of SNS-595, including less than about0.1% of N-desmethyl-SNS-595. In one embodiment, the process providedherein yields SNS-595 Substance consisting essentially of SNS-595,including less than about 0.01%, 0.02%, 0.03%, 0.04% or 0.05% ofN-desmethyl-SNS-595 based upon total weight of the composition.

In certain embodiments, the process provided herein yields SNS-595Substance consisting essentially of SNS-595, including less than about0.1% of O-desmethyl-SNS-595. In one embodiment, the process providedherein yields SNS-595 Substance consisting essentially of SNS-595,including less than about 0.01%, 0.02%, 0.03%, 0.04% or 0.05% ofO-desmethyl-SNS-595 based upon total weight of the composition.

In certain embodiments, the process provided herein yields SNS-595Substance consisting essentially of SNS-595, including less than about0.1% of total N-desmethyl-SNS-595 and O-desmethyl-SNS-595. In oneembodiment, the process provided herein yields SNS-595 Substanceconsisting essentially of SNS-595, including less than about 0.01%,0.02%, 0.03%, 0.04% or 0.05% of total N-desmethyl-SNS-595 andO-desmethyl-SNS-595 based upon total weight of the composition.

In certain embodiments, the process provided herein yields SNS-595Substance consisting essentially of SNS-595, including less than about0.1% of N,O-bisdesmethyl-SNS-595. In one embodiment, the processprovided herein yields SNS-595 Substance consisting essentially ofSNS-595, including less than about 0.01%, 0.02%, 0.03%, 0.04% or 0.05%of N,O-bisdesmethyl-SNS-595 based upon total weight of the composition.

Several methods for preparation of(3S,4S)-4-methoxy-N-methylpyrrolidin-3-amine•2TsOH are reported in theliterature (see, U.S. Pat. No. 5,817,669, WO 2007/146335, Tsumki et al.,J. Med. Chem., 47:2097-2106, 2004 and Tomita et al., J. Med. Chem., 45:5564-5575, 2002). These processes can provide products contaminated bysignificant levels of impurities including N-desmethyl- andO-desmethyl-analogs of Compound 8 and others. One such method isillustrated In Scheme 3.

As reported previously, for example, see, WO 2007/146335, Tsuzuki etal., J. Med Chem., 47:2097-2106, 2004 and Yomita et al., J. Med Chem.,45: 5504-5575, 2002, during the scale up of this process, up to 1.5% of4-methoxypyrrolidin-3-amine, i.e., N-desmethyl-compound 8, impurity wasobserved, presumably as a result of incomplete methylation of INT11 inthe INT12 step. This impurity is converted during the synthesis ofSNS-595 to the known impurity, N-desmethyl-SNS-595 as shown in Scheme 4,

In additions the process was not reproducible and the yield and amountof impurities were impacted by small variations in temperature andreaction times. Dimeric and trimeric impurities (which were difficult toremove) were formed at slightly elevated temperatures and longer boldtimes. In many instances, the levels of impurities were so high and theyield, so low that the product was difficult to crystalline.

Table 1 provides impurity profile for synthetic route illustrated inScheme 3.

TABLE 1 Impurity profile of Compound 8 prepared according to Scheme 3Compound Other Batch Size N,O- O- N- 8 impurities (output) (%) (%) (%)(%) (%)  ~0.1 kg 0.0 0.06 0.31 96.6 0.48, 0.66 ~1.28 kg 0.09 0.99 0.8394.7 0.57, 1.16  ~14 kg 0.10 0.28 1.46 96.1 0.41, 0.25

In Table 1, “N,O-” refers to N,O-bis-desmethyl-Compound 8, having theformula:

“O-” refers to O-desmethyl-Compound 8, having the formula:

“N-” refers to N-desmethyl-Compound 8, having the formula:

and“NR” means that data were not reported.

In certain embodiments, provided herein are processes tor thepreparation of SNS-595 designed to reduce or eliminate incompletemethylatlon that results in the N-desmethyl-Compound 8 impurity. Anexemplary process is depicted in Scheme 1.

In Scheme 3, the N-methyl group is introduced not by methylation, but bynucleophilic opening of the epoxide by methylamine, thereby eliminatingthe impurities resulting from incomplete methylation.

In certain embodiments, methylamine does not contain detectable quantityof ammonia. In such embodiments, Compound 4 does not contain thecorresponding N-desmethyl impurity. In certain embodiments, methylminecontains less than about 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%,0.2% or 0.1% or less ammonia.

Any impurity present can he purged by crystallisations at Compound 4,Compound 5A, and/or Compound 6 steps.

As illustrated in Scheme 1, intermediate Compound 4 can be prepared by aprocess from commercially available Boc-3-pyrroline (Compound 1), see,e.g., Tetrahedon Asymmetry, 12 (2002) 2989-2997.

Intermediate Compound 4 can be resolved by forming a complex with achiral acid. Any chiral acid deemed suitable by one of skill in the artcan be used. Exemplary chiral acids include, but are not limited tomalic acid, pyrogiutaobc acid (PGA), tartaric acid, di-p-toluoyltartaricacid (DTTA), camphor sulfonic acid (CSA), and mandelic acid.

In one embodiment, the chiral acid is L-(−)-malic acid orL-(−)-pyroglutamic acid. In one embodiment, L-(−)-malic acid reacts withCompound 4 to form Compound 5A. In one embodiment, L-(−)-pyroglutamicacid reacts with Compound 4 to form Compound 5B. In certain embodiments,about 0.25 to 2 equivalents of the chiral acid is used. In oneembodiment, about 0.5 to 1.5 equivalents of the chiral acid is used. Inone embodiment, about 0.9 to 1.1 equivalents of the chiral acid is used.In certain embodiments, about 0.25 to 2 equivalents of L-(−)-malic acidis used. In one embodiment, about 0.5 to 1.5 equivalents of L-(−)-malicacid is used. In one embodiment, about 0.9 to 1.1 equivalents ofL-(−)-malic acid is used.

In one embodiments L-(−)-malic acid produces the L-(−)-malate salt.Compound 5A, in greater than about 98%, 99%, 99.3%, 99.5%, 99.7%, 99.8%or 99.9% enantiomeric excess. In one embodiment, L-(−)-malic acidproduces the L-(−)-malate salt, Compound 5A, in up to about 100%enantiomeric excess.

The secondary amine in Compound 5A is protected by a protecting group.Any suitable protecting group, including benzyl, benzyloxycarbonylacetyl, phenylcarbonyl and t-butoxycarbonyl can be used. The methylationof free hydroxyl group is carried out with a methylating agent, such asdimethylsulfate, methyl p-toluenesulfonate, or metanesulfonate. Compound8 is obtained by removal of the protecting groups under acidicconditions. Suitable deprotectiug agents include p-toluene sulfonic acidmonohydnste. In Scheme 1, the secondary amine in Compound 5A isprotected with t-butyloxy carbonyl group, to obtain Compound 6, bytreatment with Boc₂O. Compound 6 is then methylated using methylatingconditions, such as potassium hexamethyidlsilazane (KHMDS) and Me₂SO₄ togive Compound 7. The crude product is de-protected under previouslyknown (see, Scheme 2) conditions to give Compound 8 in consistently highpurity and yield.

As described in Examples 1 and 3, this route can be scaled upsuccessfully to produce Laboratory scale batches (100 g to 1 kg scale)and cGMP batches of Compound 8 on ˜16 kg scale from commerciallyavailable Boc-3-pyrroline (Compound 1). All batches in the examples hadlittle N-desmethyl impurity (Table 2). Other related substances werealso below quantitation limits of about 0.1%. The enantiomeric purity(determined by HPLC) of Compound 8 was also high (>99.8% ee). No newimpurities were identified in the development or scale up batches.

TABLE 2 Impurity profile of Compound 8 prepared according to Scheme 1Batch Size HPLC area % (output) N,O- O- N- Compound 8 % (R,R) 66 g ND NDND 100.0 0.0 65 g ND ND ND 100.0 0.0 68 g ND ND ND 100.0 0.0 0.75 kg NDND ND 99.8 0.0 10.2 kg ND 0.03 0.03 99.7 0.08 12.2 kg ND ND ND 99.7 0.0312.1 kg ND ND 0.01 99.7 0.09 ND refers to Not detected.

In certain embodiments, enantiomeric enrichment occurs during thecrystallization, of Compound 8. In certain embodiments, the chiralpurity of Compound 8 can be enhanced by additional crystallization.

In certain embodiments, Compound 5A with as low as 90% ee is carriedforward to produce Compound 8 with >99.5% ee.

Incomplete methylation of Compound 6 results in O-desmethyl-Compound 6as a process impurity. The level of this impurity was below quantitationlimits (>0.1%) in the batches shown in Table 2. Two successful appmacheswere evaluated to control this impurity in the process.

a. In-process control in the methylation step (conversion of Compound 6to Compound 7). Current in-process control, limits are <2% Compound 6 byHPLC. When batches of Compound 7 containing up to 2% Compound 6 werecarried through Compound 8 and isolation, the levels ofO-desmethyl-Compound 6 were below 0.1%.

b. Purging of O-desmethyl-Compound 8 was shown to occur during thecrystallisation of Compound 8. Therefore, O-desmethyl-Compound 8, ifformed, can be reduced by additional crystallization.

Based on the methods described, the synthetic route illustrated inScheme 1 and described in Example 1 is robust for scale up, and canproduce Compound 8 of consistently high chemical and enantiomericpurity. Specifically, this route produces Compound 8 with little, ifany, of previously known impurities (N-desmethyl-Compound 8 andO-desmethyl-Compoond 8) and produces no new impurities.

Compound 8 produced in Scheme 1 can be further reacted with7-chloro-4-oxo-1-thiazol-2-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylicacid ethyl ester to obtain SNS-595 as described in Example 3. Fullanalytical testing of SNS-595 obtained by the process described herein,showed that no detectable new impurities were formed.

In certain embodiments, SNS-595 produced by the methods provided hereincontains less than about 0.1% N-desmethyl-SNS-595 andO-desmethyl-SNS-595. In certain embodiments, SNS-595 produced by themethods provided herein contains less than about 0.1%N-desmethyl-SNS-595. In certain embodiments, SNS-595 produced by themethods provided herein contains less than about 0.09, 0.08, 0.07, 0.06,0.05, 0.04, 0.03, 0.02 or 0.01% N-desmethyl-SNS-595. In certainembodiments, SNS-595 produced by the methods provided herein containsless than about 0.1% O-desmethyl-SNS-595. In certain embodiments,SNS-595 produced by the methods provided herein contains less than about0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02 or 0.01%O-des-methyl-SNS-595. In certain embodiments, SNS-595 produced by themethods provided herein contains less than about 0.1% totalN-desmethyl-SNS-595 and 65-desmethyl-SNS-595. In certain embodiments,SNS-595 produced by the methods provided, herein contains less thanabout 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02 or 0.01% totalN-desmethyl-SNS-595 and O-desmethyl-SNS-595.

In certain embodiments, the methods provided herein are useful inpreparing SNS-595 Substance on a process scale. In certain embodiments,the methods provided herein are useful in preparing 0.1, 0.3, 0.5, 1, 2,3, 4, 5, 7, 10, 15, 20, 25, 50, and 100 kg or more SNS-595 Substance.

5.4 Methods of Use

Provided herein are methods of treating, preventing, and/or managingvarious cancers, comprising administering SNS-595 Substance preparedaccording to the processes described herein. In certain embodiments, themethods encompass administering substantially pure SNS-595. Examples ofcancers include solid tumors and hematologic cancers. The methodsprovided herein may also be used tor treatment or prevention ofprecancerous conditions.

Accordingly, provided herein are methods of treating, managing, orpreventing cancers or precancerous conditions, comprising administeringa dose of about 10-100 mg/m² of SNS-595 Substance to a subject in needof such treatment, management or prevention. The cancer types include,but are not limited to, ovarian cancer, breast cancer, small cell lungcancer and non-small cell lung cancer. In one embodiment, the cancer isrelapsed. In one embodiment, the cancer is refractory. In oneembodiment, the cancer is resistant to conventional therapy. In oneembodiment, the cancer is ovarian cancer resistant to conventionaltherapy. In one embodiment, the cancer is platinum-resistant epithelialovarian cancer.

In one embodiment, the methods provided herein encompass treating,preventing or managing various types of leukemia in a subject, such aschronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML),acute lymphoblastic leukemia (ALL), and acute myelogenous leukemia(AML), or acute myeloblastie leukemia (AML).

In one embodiment, provided herein, are methods for treatment of acutemyeloid leukemia. In one embodiment, the methods for treatment ofrefractory or relapsed acute myeloid leukemia.

The methods provided, herein encompass treating patients who have beenpreviously treated for cancer, but are non-responsive to standardtherapies, as well as those who have not previously been treated. Alsoencompassed are methods of treating patients regardless of patient sage, although some diseases or disorders are more common in certain, agegroups. Further provided are methods of treating patients who have-undergone surgery in an attempt to treat the disease or condition atissue, as well as those who have not. Because patients with cancer haveheterogeneous clinical manifestations and varying clinical outcomes, thetreatment given to a patient may vary, depending on his/her prognosis.The skilled clinician will be able to readily determine without undueexperimentation specific secondary agents, types of surgery, and typesof non-drug based standard therapy that can be effectively used to treatan individual patient with cancer.

4.5 Dosages

In certain representative embodiments, the method of treating,preventing or managing cancers provided herein comprises administeringto a patient on the basis of body surface area, a dose of about 10mg/m²-100 mg/m² of SNS-595 Substance. In certain representativeembodiments, the method of treating, preventing or managing cancersprovided herein comprises administering to a patient on the basis ofbody surface area, a dose of about 10 mg/m²-110 mg/m² of SNS-595Substance. In certain embodiments, the methods encompass administeringsubstantially pure SNS-595. In another embodiment, the method ofcomprises administering a dose of about 20 mg/m²-90 mg/m² of SNS-595Substance. In another embodiment, the method comprises administering adose of about 40 mg/m²-80 mg/m² of SNS-595 Substance. In anotherembodiment, the method comprises administering a dose of about 30mg/m²-50 mg/m² of SNS-595 Substance. In another embodiment, the methodcomprises administering a dose of about 50 mg/m²-110 mg/m² of SNS-595Substance.

The skilled practitioner in treating cancer typically employs a dosageunit that enables approximation of the subject's exposure to the activeingredient being administered. For example, the dosage unit/used mayapproximate exposure based, on a calculation of body surface area. Bodysurface area (BSA) calculations for a human subject can be calculated,tor example, using the Mostelier formula:

BSA(m²)=[(height(cm)×body mass(kg)/3600]^(1/2).

The most common such dosage unit is milligrams of active compound persquare meter of body surface area (mg/m²).

The administered dose of the SNS-595 can be expressed in units otherthan mg/m². For example, doses can be expressed as milligrams of activecompound per kilogram of body mass (mg/kg). One of ordinary skill in theart would readily know how to convert a patient dose from mg/m² tomg/kg, given the height and/or body mass of the patient (see,http://www.fda.gov/cder/cancer/animalframe.htm. For example, a dose of 1mg/m²-30 mg/m² for a 65 kg human is approximately equal to 0.026mg/kg-0.79 mg/kg. Other dosage units may also be employed.

In certain embodiments, the administered dose of SNS-595 Substanceprovided herein can be delivered as a single bolus (e.g., intravenousinjection) or over a longer period (e.g., continuous infusion orperiodic bolus doses). Administration of SNS-595 Substance may berepeated until the subject experiences stable disease or regression oruntil the subject experiences disease progression or unacceptabletoxicity. Stable disease or lack thereof is determined by methods knownin the art, such as evaluation of symptoms, physical examination, andother commonly accepted parameters.

The amount of SNS-595 Substance administered according to the methodsprovided herein will depend on various factors, such as the overallhealth of the patient being treated, the severity of the disorder orsymptom of the disorder, the active ingredient being administered, themanner of administration, the frequency of administration, othermedications present, and the judgment of the prescribing physician. Theamount to be administered can be empirically determined by thephysician.

In some embodiments, the frequency of administration is in the range ofabout a daily dose to about a monthly dose. In certain embodiments,administration is once per day, once every other day, once per week,twice per week, three times per week, once every two weeks, once everythree weeks, or once every four weeks. In one embodiment, thepharmaceutical composition provided herein is administered once per weekfor three weeks. In another embodiment, the pharmaceutical compositionprovided herein is administered once per week for three weeks. In oneembodiment, the pharmaceutical composition provided herein isadministered once every three weeks. In another embodiment, thepharmaceutical composition provided herein Is administered once everyfour weeks.

In certain embodiments, SNS-595 Substance provided herein isadministered to a patient in one or more cycles of administration.Cycling therapy involves the administration of one or more doses ofSNS-595 Substance, followed by a period of rest, and repeating thisadministration/rest cycle. Cycling therapy can reduce the development ofresistance to one or more of the therapies, avoid or reduce the sideeffects of one or more of the therapies, and/or improve the efficacy orduration of the treatment.

Consequently, in one embodiment, SNS-595 Substance provided herein isadministered once per week, in a single dose or in divided doses, in athree- to six-week cycle with a rest period of about 1 to about 30 daysbetween doses. In some embodiments, the waiting period is 14 days, withthe first dose given on day 1 and the next dose given on day 15.Treatment in such cases may thus be said to be using a “14-day cycle.”In some embodiments, the doses may be given 28 days apart, i.e., a28-day cycle.

In another embodiment, the dosing method comprises a cycle wherein thecycle comprises administering a dose of SNS-595 Substance to a patientonce per week for three weeks followed by a period of at least 14 daysin which no compound or composition is administered to the patient andwherein the cycle is repeated a plurality of times. In anotheranbodimcnt, the period in which no compound or composition isadministered is 18 days. In another embodiment, the period in which nocompound or composition is administered is 21 days. In anotherembodiment, the period in which no compound or composition isadministered is 28 days. The frequency, number and length of dosingcycles can be increased or decreased.

In one embodiment, the method provided herein comprises: i)administering a dose of about 40-80 mg/m² of SNS-595 Substance providedherein to a patient; ii) waiting a period of at least six days where thepatient is not administered any SNS-595 Substance; and iii)administering another dose of about 40-80 mg/m² of SNS-595 Substance tothe patient. In one embodiment, steps ii)-iii) are repeated a pluralityof times.

In one embodiment, the method provided, herein comprises: i)administering a dose of about 30-50 mg/m² of SNS-595 Substance providedherein to a patient; ii) waiting a period of at least six days in whichthe patient is not administered any SNS-595 Substance; and iii)administering another dose of about 30-50 mg/m² of SNS-595 Substance tothe patient. In one embodiment, steps ii)-iii) are repeated a pluralityof times.

In one embodiment the method provided herein comprises; i) administeringa dose of about 50-110 mg/m² of SNS-595 Substance provided herein to apatient; ii) waiting a period of at least six days where the patient isnot administered, any SNS-595 Substance; and iii) administering anotherdose of about 50-110 mg/m² of SNS-595 Substance to the patient. In oneembodiment, steps ii)-iii) are repeated a plurality of times.

In another embodiment, the method comprises administering a dose ofabout 40 mg/m², about 45 mg/m², about 48 mg/m², about 50 mg/m², about 60mg/m², about 72 mg/m², about 75 mg/m², about 80 mg/m², or about 90 mg/m²of SNS-595 Substance provided herein, in each, of the foregoing steps i)and iii).

In another embodiment, provided herein is a method for treatment ofsolid tumors comprising administering a dose of about 48 mg/m² ofSNS-595 Substance provided herein to a patient once every three weeks.In another embodiment, provided herein, is a method for treatment ofsuch solid tumors comprising administering a dose of about 60 mg/m² ofSNS-595 Substance provided herein to a patient once every four weeks. Inanother embodiment, provided herein is a method for treatment of suchsolid tumors comprising administering a dose of about 75 mg/m² ofSNS-595 Substance provided herein to a patient once every four weeks. Insuch embodiments, the method may be used for treatment of ovariancancer, such as platinum-resistant epithelial ovarian cancer.

In another embodiment, provided herein is a method for treatment ofleukemia, comprising administering a dose of about 50 mg/m² of SNS-595Substance provided herein to a patient once per week. In anotherembodiment, provided herein is a method for treatment of leukemia,comprising administering a dose of about 60 mg/m² of SNS-595 Substanceprovided herein to a patient once per week. In another embodiment,provided herein is a method for treatment of leukemia comprisingadministering a dose of about 72 mg/s² of SNS-595 Substance providedherein to a patient once per week. In another embodiment, providedherein is a method for treatment of letrkemia comprising administering adose of about 72 mg/m² of SNS-595 Substance provided herein to a patientonce per week for two weeks. In another embodiment, provided herein is amethod for treatment of leukemia comprising administering a dose ofabout 72 mg/m² of SNS-595 Substance provided herein to a patient onceper week for three weeks. In another embodiment, provided herein is amethod for treatment of leukemia comprising administering a dose ofabout 90 mg/m² of SNS-595 Substance provided herein to a patient onceper week for three weeks. In another embodiment, provided herein is amethod for treatment of leukemia, comprising administering a dose ofabout 40 mg/m² of SNS-595 Substance provided herein to a patient twiceper week. In one embodiment, the method is for treatment of acutemyeloid leukemia.

In certain embodiments, the dosing method comprises administering to asubject a dose of SNS-595 Substance twice per week for two weeks (dosingon days 1, 4, 8 and 11). In another embodiment, the dosing methodcomprises administering a once-per-week dose of SNS-595 Substance to asubject. In another embodiment, the dosing method comprisesadministering a dose of SNS-595 Substance to a subject once every twoweeks. In another embodiment, the dosing method comprises administeringa dose of SNS-595 Substance to a subject once every three weeks. Inanother embodiment, the dosing method comprises administering a dose ofSNS-595 Substance to a subject once every four weeks.

In one embodiment, a dose of about 40-80 mg/m² of SNS-595 Substance isadministered to a patient once every three weeks wherein the three-weekperiod comprises a treatment cycle and the treatment cycle is repeatedat least one time. In another embodiment, the method comprisesadministering a dose of about 40-80 mg/m² of SNS-595 Substance to apatient once every four weeks wherein the four-week period comprises atreatment cycle and the treatment cycle is repeated at least one time.In another embodiment, the method comprises administering a dose ofabout 48 mg/m² of SNS-595 Substance to a patient once every three weekswherein the three-week period, comprises a treatment cycle and thetreatment cycle is repeated at least one time. In another embodiment,the method comprises administering a dose of about 60 mg/m² of SNS-595Substance to a patient once every hour weeks wherein the four-weekperiod comprises a treatment cycle and the treatment cycle is repeatedat least one time, in another embodiment, the method comprisesadministering a dose of about 75 mg/m² of SNS-595 Substance to a patientonee every four weeks wherein the four-week period comprises a treatmentcycle and the treatment cycle is repeated at least one time.

In one embodiment, the method comprises administering a dose of about40-80 mg/m² of SNS-595 Substance to a patient once per week wherein theone-week period comprises a treatment cycle and the treatment cycle isrepeated at least three times. In one embodiment, the method comprisesadministering a dose of about 59-110 mg/m² of SNS-595 Substance to apatient once per week wherein the one-week period comprises a treatmentcycle and the treatment cycle is repeated at least three times. Inanother embodiment, the method comprises administering a dose of about30-50 mg/m² of SNS-595 Substance to a patient twice per week wherein theone-week period comprises a treatment cycle and the treatment cycle isrepeated at least two times. In another embodiment, the dose is about 50mg/m² of SNS-595 Substance once per week wherein the one-week period,comprises a treatment cycle and the treatment cycle is repeated at leastthree times. In another embodiment, the dose is about 60 mg/m² ofSNS-595 Substance once per week wherein the one-week period comprises atreatment cycle and the treatment cycle is repeated at least threetimes. In another embodiment, the dose is about 72 mg/m² of SNS-595Substance once per week wherein the one-week period comprises atreatment cycle and the treatment cycle is repeated at least threetimes. In another embodiment, the dose is about 90 mg/m² of SNS-595Substance once per week wherein the one-week period comprises atreatment cycle and the treatment cycle is repeated at least threetimes. In another embodiment, the method comprises administering a doseof 40 mg/m² of SNS-595 Substance to a patient twice per week wherein theone-week period comprises a treatment cycle and the treatment cycle isrepeated at least two times. In certain embodiments, the methodsencompass administering substantially pure SNS-595.

All methods and dosages described herein apply to the treatment orprevention of cancer or precancerous condition.

4.6 Second Active Agents

It will also bo appreciated that SNS-595 Substance and pharmaceutical,compositions comprising SNS-595 Substance prepared according to themethod described herein can be employed. In complementary combinationtherapies with, other active agents or medical procedures, in certainembodiments, substantially pure SNS-595 is used in combinationtherapies.

SNS-595 Substance and pharmaceutical compositions thereof can beadministered concurrently with, prior to, or subsequent to, one or moreother desired active agents or medical procedures. The particularcombination of therapies (agents or procedures) to employ in acombination regimen will take into account compatibility of the desiredtherapeutics and/or procedures and the desired therapeutic effect to beachieved. It will also be appreciated that the therapies employed mayachieve a desired effect for the same disorder (for example, SNS-595Substance may be administered concurrently with another active agentused to treat the same disorder), or they may achieve different effects(e.g., control of any adverse effects). Non-limiting examples of suchagents and procedures include surgery, radiotherapy (e.g.,gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy,proton therapy, brachytherapy, and systemic radioisotopes), endocrinetherapy, biologic response modifiers (interferons, interleukins, andtumor necrosis factor (TNF) to name a few examples), hyperthermia andcryotherapy, agents to attenuate any adverse effects (e.g., antiemeticagents), and other approved ehemotherapetitle anticancer agents.

Examples of chemotherpeutic anticancer agents that may be used as secondactive agents in combination with SNS-595 Substance include, but are notlimited to, alkylating agents (e.g., mechlorethamine, chlorambucil,cyclophosphamide, melphalan, ifosfamide), antimetabolites (e.g.,methotrexate), aurora kinase inhibitors (e.g., SNS-314), purineantagonists and pyrimidine antagonists (e.g., 6-mercaptopurine,5-fluorouracil (5-FU), cytarabine (Ara-C), gemcitabine), spindle poisons(e.g., vinblastine, vincristine, vinorelbine, paclitaxel),podophyllotoxins (e.g., etoposide, irinotecan, topotecan), antibiotics(e.g., doxorubicin, daunorubicin, bleomycin, mitomycin), nitrosoureas(e.g., carmustine, lomustine), inorganic ions (e.g., platinum complexessuch as cisplatin, carboplatin), enzymes (e.g., asparaginase), hormones(e.g., tamoxifen, leuprolide, flutamide, and megestrol), topoisomeraseII inhibitors or poisons, EGFR (Her1, ErbB-1) inhibitors (e.g.,gefitnib), antibodies (e.g., bevaclzumab, rituximab), IMIDs (e.g.,thalidomide, lenalidomide), various targeted agents (e.g., HDACinhibitors such as vorinostat), Bcl-2 inhibitors, VEGF inhibitors,proteasome inhibitors (e.g., bortezomib), cyclin-dependent kinase (cdk)inhibitors (e.g., SNS-032, selieielib), and dexamethasone.

In one embodiment, examples of chemotherapeutic anticancer agents thatmay be used as second active agents in combination with SNS-595Substance include, docetaxel, vinorelbine, capeccitabine, doxorubicin,gosereli, zoledronic acid, paclitaxel pamidronate, anastrozole,exemestane, cyclophosphamide, epirabicin, fulvestrant, letrozole,gemcitabine, leuprolide, filgrastim (G-CSF or granulocyte colonystimulating factor), toremifene, tamoxifen, pegfilgrastim, epoetin, alfaand darbepoetin alfa. In certain embodiments, SNS-595, in combinationwith these second agents, can be used for the treatment of breastcancer.

Some specific anticancer agents that can be used in combination withSNS-595 Substance include, but are not limited to: cytarabine,carboplatin, cisplatin, gemcitabine, and combinations of any two or morethereof.

4.7 Combination Therapy with a Second Active

In certain embodiments, the method provided herein comprisesadministering SNS-595 Substance or pharmaceutical compositions providedherein in combination with one or more second active agents, and/or incombination with radiation therapy or surgery. In certain embodiments,the methods encompass administering substantially pure SNS-595 incombination with one or more second active agents, and/or in combinationwith radiation therapy or surgery.

The administration of SNS-595 Substance and the second active agents toa patient can occur simultaneously or sequentially by the same ordifferent routes of administration. The suitability of a particularroute of administration employed for a particular active agent willdepend on the active agent itself (e.g., whether it can be administered,orally without decomposing prior to entering the blood stream) and thedisease being treated. Recommended routes of administration tor thesecond active agents are known to those of ordinary skill in the art.See, e.g., Physicians' Desk Reference, 1755-1760 (56^(th) ed., 2002)(hereinafter “Physicians' Desk Reference”).

In one embodiment, the second active agent is administered intravenouslyor subcutaneousiy and once or twice daily in an amount of from about 1to about 1,000 mg, from about 5 to about 500 mg, from about 10 to about375 mg or from about 50 to about 200 mg.

In another embodiment, provided herein are methods of treating,preventing and/or managing hematologic malignancies, which compriseadministering SNS-595 Substance provided herein in conjunction with(e.g., before, daring or after) conventional therapy including, but notlimited to, surgery, immunotherapy, biological therapy, radiationtherapy or other non-drug based therapy presently used to treat, preventor manage cancer,

In one embodiment, SNS-595 Substance can be administered in an amount ofabout 10-100 mg/m², 20-90 mg/m², 40-80 mg/m², or 30-50 mg/m², alone orin combination with a second active agent disclosed herein (see, e.g.,section 4.6), prior to, during, or after the use of conventionaltherapy.

In one embodiment, the second agent is selected from the groupconsisting of cytarabine, carboplatin, cisplatin, gemcitabine, andcombinations any two or more thereof.

In certain embodiments, SNS-595 Substance may be administered incombination with about 5 to 1500 mg/m² of cytarabine. For example, oneembodiment includes continuous daily administration of cytarabine at adose of about 200 to 400 mg/m². The administration of cytarabine can bemade by intravenous infusion, intravenous push, bolus injection orsubcutaneous injection. In certain embodiments, the administration ofcytarabine is daily, e.g., for 5 days, wink the administration ofSNS-595 occurs once or twice per week. As discussed herein, theadministration of SNS-595 and cytarabine as set forth above in a week isconsidered a weekly cycle. The methods encompass performing one weeklycycle, waiting a period of one week to several weeks where neithercytarabine nor SNS-595 is given then repeating a weekly cycle. Themethods also contemplate repeating the weekly cycles continuously, forexample, for 4 weeks or 28 days. In addition, the methods contemplaterepeating the cycle for several cycles, waiting a period of a week toseveral weeks where neither cytarabine not SNS-595 Substance is giventhen repeating one or more cycles. Finally, the methods provideadministration of a SNS-595 Substance/cytarabine weekly cycle followedby a cycle of only cytarabine or SNS-595.

Also provided are methods in which the daily cytarabine isadministration is at a dose of about 5-50 mg/m² and where SNS-595Substance is administered once per week or twice per week. For example,the cytarabine may be administered daily for 10 days, and SNS-595Substance may be administered on a schedule of once per week for threeweeks, or twice per week for two weeks.

Use of SNS-595 Substance with cytarabine may be employed, for example,in the treatment of leukemias, such as acute myeloid leukemia. In oneexemplary embodiment, a treatment cycle may be used that comprisesadministering to a patient about 20-90 mg/m² or about 40-80 mg/m² ofSNS-595 Substance on days 1 and 4 of a 28-day cycle, and administeringto the patient about 400 mg/m² of cytarabine on days 1-5 of the cycle.In such a method, the doses of SNS-595 Substance may be administered byintravenous (IV) injection, and the doses of cytarabine by continuousintravenous (CIV) infusion. In an alternative exemplary embodiment, apatient having AML may be treated using a treatment cycle comprisingadministering to the patient about 20-90 mg/m² or about 40-80 mg/m² ofSNS-595 Substance on days 1 and 4, and administering to the patientabout 1000 mg/m²/day on days 1 -5. In such a method, the doses ofSNS-595 Substance may be administered by IV injection, and the doses ofcytarabine by IV infusion over two hours.

In one embodiment, the combination therapy comprises administeringSNS-595 Substance and carboplatin. In one embodiment, the combinationtherapy comprises administering SNS-595 Substance and cisplatin. In oneembodiment, the combination therapy comprises administering SNS-595Substance and gemcitabine.

In one embodiment, the methods provided include the administration ofSNS-595 Substance in combination with about 5 mg/m² to about 200 mg/m²cisplatin. For example, one embodiment includes administration ofcisplatin at a dose of about 50 or 70 mg/m³ once every 3 to 4 weeks. Oneembodiment includes admlnistmtion of cisplatin at a dose of about 50 or70 mg/m² once every 3 weeks. Another embodiment includes administrationof cisplatin at a dose of about 75 or 100 mg/m² once every 3 weeks. Inanother embodiment, administration of cisplatin is at a dose of about 20mg/m² dally for up to 5 days. The administration of cisplatin can bemade by intravenous infusion, intravenous push, bolus injection orsubcutaneous injection. In one embodiment, the administration ofcisplatin is once every 3 to 4, weeks, while the administration ofSNS-595 Substance occurs once per week for three weeks or once everythree weeks. In one embodiment, the administration, of cisplatin isdaily for 5 days, while the administration of SNS-595 Substance occursonce per week for three weeks or once every three weeks. In oneembodiment, the administration of cisplatin is once a week for 3 weeks,while the administration of SNS-595 Substance occurs once per week forthree weeks or once every three weeks.

In one embodiment, the methods provided include the administration ofSNS-595 Substance in combination with about 50 mg/m² to about 400 mg/m²carboplatin. For example, one embodiment includes administration ofcarboplatin at a dose of about 300 or about 360 mg/m² once every 3weeks. One embodiment includes administration of carboplatin at a doseof about 300 or 360 mg/m² once every 4 weeks. The administration ofcarboplatin can be made by intravenous infusion, intravenous push, bolusimection or subcutaneous injection. In one embodiment, theadministration of carboplatin is once every 3 weeks, while theadministration, of SNS-595 Substance occurs once per week for threeweeks or once every throe weeks. In one embodiment, the administrationof carboplatin is once a week for 3 weeks, while the administration ofSNS-595 Substance occurs once per week for three weeks or once everythree weeks.

In one embodiment, the methods provided include the administration ofSNS-595 Substance in combination with about 100 mg/m² to about 1500mg/m² gemcitabine. For example, one embodiment includes administrationof gemcitabine at a dose of about 1000 or 1250 mg/m² once every week forat least 4 weeks. The administration, of gemcitabine can he made byintravenous infusion, intravenous push, bolus injection or subcutaneousinjection. In one embodiment, the administration of gemcitabine is oncea week for up to 4 weeks, while the administration of SNS-595 Substanceoccurs once per week for three weeks or once every three weeks. In oneembodiment, the administration of gemcitabine is twice a week for 2weeks, while the administration, of SNS-595 Substance occurs once perweek for three weeks.

In certain embodiments, the second active agent is co-administered withSNS-595 Substance provided herein or administered with 1-50 hours delay.In certain embodiments, SNS-595 Substance provided herein isadministered first followed by administration with the second activeagent with 1-50 hours delay. In other embodiments, the second activeagent is administered first followed by administration of SNS-595Substance provided herein with 1-50 hours delay. In some embodiments,the delay is 24 hours.

In another embodiment, the method provided herein comprises: a)administering to a patient in need thereof, a dose of about 10-100 mg/m²of SNS-595 Substance provided herein and b) administering atherapeutically effective amount of a supportive care agent.

The supportive care agent is any substance that treats, prevents,manages, avoids or reduces an adverse or unwanted effect from treatmentwith SNS-595 Substance provided herein and is administered according tothe appropriate dosing regimen for that substance. For example,different supportive care agents for treating nausea have differentdosing regimen. While some such agents are administeredprophylactically, others are co-administered with a compound orcomposition provided herein while still others are administered afterthe administration of SNS-595. Illustrative examples of supportive careagents their doses and dosing regimens are found in Physicians' DeskReference. Some exemplary support eare agents are disclosed in U.S.Application Pub. No. 2000-0025437, which incorporated by reference inits entirety.

4.8 Pharmaceutical Compositions and Dosage Forms

The methods provided herein use pharmaceutical compositions containingSNS-595 Substance provided herein and pharmaceutically acceptablecarriers, such as diluents or adjuvants, or in combination with otheractive ingredient, such as another anti-cancer agent. In certainembodiment, the methods encompass use of pharmaceutical compositionscontaining substantially pure SNS-595. In clinical practices SNS-595Substance may be administered by any conventional route, including butnot limited to orally, parenterally, rectally or by inhalation (e.g., inthe form of aerosols). Parenteral dosage forms can be administered topatients by various routes including, but not limited to, subcutaneous,intravenous (including bolus injection), intramuscular, andintraarterial. Because their administration typically bypasses patients'natural defenses against contaminants, parenteral dosage forms aresterile or capable of being sterilized prior to administration to apatient. Examples of parenteral dosage forms include, but are notlimited to, solutions ready for injection, dry products ready to bedissolved or suspended in a pharmaceutically acceptable vehicle forinjection, suspensions ready for injection, and emulsions. In oneembodiment, SNS-595 Substance is administered by an IV injection.

The pharmaceutical compositions for parenteral administration can beemulsions or homogeneous solutions. Suitable vehicles that can be usedto provide parenteral dosage forms are well known to those skilled inthe art. Examples include, but are not limited to: Water for injectionUSP; aqueous vehicles such as, but not limited to Sodium ChlorideInjection, Ringer's Injection, Dextrose Injection, Dextrose and SodiumChloride Injection, and Laetated Ringer's Injection; water-misciblevehicles such as, but not limited to, ethyl alcohol, polyethyleneglycol, and polypropylene glycol; and non-aqneous vehicles such as, butnot limited to, petroleum oil, oil of animal, vegetable or syntheticorigin, such as peanut oil, soybean oil, mineral oil, sesame oil and thelike, ethyl oleate, isopropyl myristate, and bensyl benzoate.

These pharmaceutical compositions can also contain adjuvants, inparticular wetting, isotonizing, emulsifying, dispersing, andstabilizing agents. Sterilization can be carried out in several ways,for example using a 0.2 micron filter, by radiation or by heating (see,Remington's Pharmaceutical Sciences, 21st ed., Mack Publishing, Easton,Pa. (2005) (hereinafter “Remington's Pharmaceutical Sciences”). They canalso be prepared in the form of sterile solid pharmaceuticalcompositions which can be dissolved at the time of use in sterile wateror any other injectable sterile medium.

Pharmaceutical compositions can be used in the preparation ofindividual, single unit dosage forms. Pharmaceutical compositions anddosage forms comprise compound and one or more exeipients.

Pharmaceutical compositions and dosage forms can also comprise one ormore additional active ingredients. Examples of optional second, oradditional, active ingredients are disclosed herein.

In certain embodiments, the pharmaceutical composition provided hereinis a single unit dosage form. Pharmaceutical cooiposiiions and singleunit dosage forms provided herein comprise a prophylactically ortherapeutically effective amount of compound or composition, andtypically one or more pharmaceutically acceptable carriers orexcipients. The term “carrier” refers to a diluent, adjuvant (e.g.,Freund's adjuvant (complete and incomplete)), exeiplent, or vehicle withwhich the therapeutic is administered. Examples of suitablepharmaceutical carriers are described in Remington's PharmaceuticalSciences.

Typical pharmaceutical compositions and dosage forms comprise one ormore exeipients. Suitable exeipients are well-known to those skilled inthe art of pharmacy, and non limiting examples of suitable exeipientsinclude starch, glucose, lactose, sucrose, gelatin, malt, rice, flour,chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodiumchloride, dried skim milk, glycerol, propylene, glycol water, ethanoland the like. Whether a particular excipient is suitable forincorporation into a pharmaceutical composition or dosage form dependson a variety of factors well known in the art including, but not limitedto, the way in which the dosage form will be administered to a subjectand the specific active ingredients in the dosage form. Thepharmaceutical composition or single unit dosage form, if desired, canalso contain minor amounts of wetting or emulsifying agents, or pHbuffering agents.

Compounds that increase the solubility of one or more of the activeingredients disclosed herein can also be incorporated into theparenteral dosage forms. For example, cyclodexirin and its derivativescan be used to increase the solubility of active ingredients. See, e.g.,U.S. Pat. No. 5,134,127, which is incorporated herein by reference.

The pH of a pharmaceutical composition or dosage form may also beadjusted, to improve delivery of one or more active ingredients.Similarly, the polarity of a solvent carrier, its ionic strength, ortonicity can be adjusted to improve delivery. Compounds such asstearates can also be added to pharmaceutical compositions or dosageforms to advantageously alter the hydrophiiieity or Ilpophilielty of oneor more active ingredients so as to improve delivery. In this regard,stearates can serve as a lipid vehicle for the formulation, as anemulsifying agent or surfactant, and as a delivery-enhancing orpenetration-enhancing agent. Different salts, hydrates or solvates ofthe active ingredients can be used to further adjust the properties ofthe resulting pharmaceutical composition

Further provided herein are pharmaceutical compositions and dosage formsthat comprise one or more compounds that reduce the rate by which anactive ingredient will decompose. Such compounds, which are referred toherein as “stabilizers” include, but are not limited to, antioxidantssuch as ascorbic acid, pH buffers, or salt buffers.

The pharmaceutical compositions and single unit dosage forms can takethe form of solutions, suspensions, emulsion, powders and the like. Suchcompositions and dosage forms will contain a prophylactically ortherapeutically effective amount of a prophylactic or therapeutic agent,in certain, embodiments, in purified form, together with a suitableamount of carrier so as to provide the form for proper administration tothe subject. The formulation should suit the mode of administration. Inone embodiment, the pharmaceutical compositions or single unit dosageforms are sterile and in suitable form for administration to a human orother subject.

A pharmaceutical composition provided herein is formulated to becompatible with its intended route of administration. Examples of routesof administration include, but are not limited to, parenteral routes(i.e., other than through the digestive tract), e.g., intravenous,intradermal, subcutaneous, intramuscular, inhalation, intranasal,transdermal, topical, transmucosak intra-tumoral, and intra-synovialadministration. In a specific embodiment, the composition is formulatedin accordance with routine procedures as a pharmaceutical compositionadapted for intravenous, subcutaneous, intramuscular, intranasal ortopical administration to human beings. In certain, embodiments, apharmaceutical composition is formulated in accordance with routineprocedures for subcutaneous administration to human beings. In oneembodiment, pharmaceutical compositions for intravenous administrationare solutions in sterile isotonic aqueous buffer. Where necessary, thepharmaceutical composition may also include a solubiiizmg agent and alocal anesthetic such as lignocaine to ease pain at the site of theinjection.

Examples of dosage forms include, but are not limited to: liquid dosageforms suitable for parenteral administration to a subject; and sterilesolids (e.g., crystalline or amorphous solids) that can be reconstitutedto provide liquid dosage forms suitable for parenteral administration toa subject. An exemplary solid form is a lyophilized solid.

The pharmaceutical composition, shape, and type of dosage forms providedherein will typically vary depending on their use. For example, a dosageform used, in the initial treatment of disease may contain largeramounts of one or more of the active ingredients it comprises than adosage form used in the maintenance treatment of the same infection.Similarly, a parenteral dosage form may contain smaller amounts of oneor more of the active ingredients it comprises than an oral dosage formused, to treat the same disease or disorder. These and other ways inwhich specific dosage forms encompassed herein, will vary from oneanother will he readily apparent to those skilled in the art See, e.g.,Remington's Pharmaceutical Sciences.

Generally, the ingredients of pharmaceutical compositions providedherein are supplied either separately or mixed together in unit dosageform, for example, as a dry lyophllked powder or water free concentratein a hermetically sealed container such as an ampoule or sachetteindicating the quantity of active agent. Where the pharmaceuticalcomposition is to be administered by infusion, it can be dispensed withan infusion bottle containing sterile pharmaceutical grade water orsaline. Where the pharmaceutical composition is administered byinjection, an ampoule of sterile water for injection or saline can beprovided so that the ingredients may be mixed prior to administration.In one embodiment, dosage forms provided herein comprise sufficientSNS-595 Substance to permit administration of doses of SNS-595 Substancewithin the range of about 10-100 mg/m² per day, or per week, given as asingle once-a-day dose or as divided doses throughout the day,optionally taken with food.

In certain embodiments, the pharmaceutical dosage forms provided hereincomprise a primary container comprising SNS-595 Substance. In certainembodiments, the primary container is within an opaque secondarycontainer. In one embodiment, the primary container is a glass vial,such as a clear glass vial and the secondary container is an opaquefoil-lined pouch, including an opaque metal, foil-lined pouch, such asan opaque aluminum foil-lined pouch. In one embodiment thepharmaceutical dosage forms provided herein, comprise a clear glass vialcomprising SNS-595 Substance, wherein the clear glass vial is within anopaque aluminum foil-lined pouch. Further, exemplary pharmaceuticaldosage forms include those described in WO 2008/016668, incorporated byreference in its entirety. In one embodiment, the dosage forms providedherein comprise about 1-2000, 1-1000, 1-500, 1-300, 1-100 or 1-50 mg ofSNS-595 Substance. Particular dosage forms provided herein compriseabout 10, 15, 18, 20, 24, 25, 30, 40, 48, 50, 60, 70, 72, 75, 80, 90,100, 150, 200, 300 or 500 mg of SNS-595 Substance.

5. EXAMPLES

Certain embodiments of the claimed subject matter are illustrated by thefollowing non-limiting examples.

The following abbreviations are used in the examples:

Boc₂O=di-tert-butyl-dicarbonate

KHMDS=potassium hexamethyldisilazane

DBDMH=1,3-dibromo-5,5-dimethylhydrantoin.

TsOH=p-toluene sulfonic acid monohydrate

CDI=carbonyldiimidazole

PGA=pyroglutamaric acid

DTTA=di-p-toluoyltartaric acid

CSA=camphor sulfonic acid,

DBTA=dibenzoyltartaric acid,

ACN=acetonitrile,

IPA=isopropyl alcohol,

MeOH=methanol,

THF=tetrahydrofuran and

MTBE=methyl tert-butyl ether.

Example 1 Preparation of (+)-(4-methoxy-pyrrolidin-3-yl)-methyl-amine

(±)-3-Bromo-4-hydroxy-pyrrolidine-1-carboxylic acid, tert-butyl ester(2), (Tetrahedron Asymmetry, 12 (2002) 2989-2997)

N-Boc-3-pyrroline 1 (296 g, 1.75 moles) was added to a slurry of1,3-dibromo-5,5-dimethylhydantoin (270 g, 0.94 moles) in acetonitrile(ACN, 1800 mL) and water (296 mL), while maintaining the temperature ofthe vessel at 0 to 10° C. After the addition, the reaction mixture waswarmed to room temperature and stirred until the reaction was judged tobe complete (TLC or HPLC). The reaction was quenched, by the addition of5% aqueous sodium thiosuifate solution (600 mL) and the product wasextracted with dichloromethane (2×750 ml). The combined organic layerwas washed with water (300 mL) and brine (200 mL). The organic layer wasdried over anhydrous Na₂SO₄ (75 g) and concentrated, under reducedpressure to give 2 (450 g) which was directly used in the nest step.

6-Oxa-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid, tert-butyl ester(3). An aqueous solution of sodium, hydroxide (NaOH, 1.55 L, 2N) wasadded to compound 2 (450 g, 1.69 moles) and the reaction was stirred,between for 2 hr at about room temperature. The product was extractedwith dieihorerneihane (2×1.25 L) and the combined organic layer waswashed with water (2×750 mL) to neutral pH and then dried over anhydrousNa₂SO₄. Evaporation under reduced pressure gave the epoxide 3 (291.0 g).

(±)-3-Hydroxy-4-methylamino-pyrrolidine-1-carboxylic acid, tert-butylester (4). Aqueous methylaonne solution (40% solution, 812 mL, 3.8 mol)was added to the epoxide 3 (140 g, 0.65 mol) at room temperature and thereaction was stirred until complete. The excess methylamine was removedby distillation under reduced pressure. To the residue obtained,diisopropyl ether (800 mL) was added and the mixture stirred for about30 min. The solid was filtered, washed with diisopropyl ether (200 mL),then dried to give compound 4 (135 g).

(±)-3-Hydroxy-4-methylamino-pyrrolidine-1-carboxylic acid, tert-butylester (4), from 2.

Ten grams (10 g) of bromohydrin 2 was treated with 40% aqueousmethylamine (50 mL) and sodium bicarbonate (3.1 g) at room temperatureto give Compound 4 (8.5 g).

Resolution of (±)-3-Hydroxy-4-methylamino-pyrrolidine-1-carboxylic acid,tert-butyl ester, using L-(−)-malic acid. The aminoalcohol 4 (100 g,0.46 moles) was dissolved in a mixture of acetone (600 mL) and water (13mL) at room temperature. The reaction mixture was heated to about 40° C.and L-(−)-malic acid (62 g, 0.48 moles) was added. The mixture washeated to about 50 to 55° C. to form a clear solution, and thengradually cooled to room temperature and then to 5 to 10° C. Thecrystals formed were filtered, washed with acetone (2×70 mL), and driedunder reduced pressure to give the malate salt 5A (60 g, 37%), withpurity by chlrai HPLC ratio of S to R enantiomers (S:R)=100:0.

A small sample was analyzed for enantiomeric purity by conversion tocompound 6 and analyzing the resulting 6 by chiral HPLC (Chiracel OD-HSC\522; mobile phase: hexane:IPA 95:5; 1 mL/min). The retention time forthe S-enantiomer is 7.725 min.

Resolution of (±)-3-Hydroxy-4-methylamino-pyrrolidine-1-carboxylic acid,tert-butyl ester, using (L)-(−)-pyroglutamic acid. Resolution of 4 (10 )with (L)-(−)-pyroglutamic acid (3.58 g) in acetone (120 mL) and water (4mL) gave the pyroglutamate salt (5.7 g). Crystallisation, fromacetone-water gave 4.2 g of the PGA salt with 94:6 ratio ofdiastereomers. An additional recrystallization from acetone-water gavethe diastereomerically pure PGA salt (2.3 g, >99% de).

Preparation of3-(tert-Butoxycarbonyl-methyl-amino)-4-hydroxypyrrolidine-1-carboxylicacid, tert-butyl ester (6) from L-(−)-malic acid salt (5A).

To a mixture of compound 5A (57 g, 0.16 moles) in methanol (MeOH, 220mL), K₂CO₃ (68.0 g, 0.49 moles) was added at room temperature. Bocanhydride (40 g, 0.18 moles) was added dropwise to the reaction mixtureover about 1 hr and the reaction, mixture was stirred, until thereaction was complete (about 2 hr). Methanol was distilled off underreduced pressure at about 55 to 60° C., water (150 mL) was added to thereaction mixture and the product was extracted with methyl tert-butylether (MTBE, 2×150 mL). The combined organic layer was washed with water(200 mL) and brine (100 mL), and then dried over anhydrous Na₂SO₄.Concentration under reduced pressure gave compound 6 as a white solid(52 g).

3-(tert-Butoxycarbonyl-methyl-amino)-4-methoxy-pyrrolidine-1-carboxylicacid, tert-butyl ester (7).

A suspension of 6 (52 g, 0.16 mol) in tetrahydrofuran (THF, 150 mL) wasstirred at room temperature for about 30 min and cooled to −10 to −15°C. A solution of potassium hexamethyldisilylamide (KHMDS, 40% solutionin THF, 144 mL, 0.256 mol) was slowly added while controlling thetemperature between −5 and −15° C. After 15 min, dimethyl sulfate (18.7mL, 1.20 mol) was added dropwise to the reaction mixture whilemaintaining a temperature between −10 and 0° C., and the resultingreaction mixture was then stirred at this temperature for about 30 min.The reaction mixture was quenched by the addition of water (100 mL),followed by acetic acid (50 mL). The product was extracted with methyltert-butyl ether (2×150 mL). The combined organic layer was washed withwater (100 mL), brine (50 mL) and dried over anhydrous Na₂SO₄.Evaporation under reduced pressure gave compound 7 as an oil (54 g).

(+)-(4-Methoxy-pyrrolidin-3-yl)-methyl-amine, Prepared usingtoluene-4-sulfonic acid (2:1). To a solution of compound 7 (54.0 g,0.163 moles) in THF (180 mL) and MeOH (90 mL), p-toluene sulfonic acidmonohydrate (84 g, 0.442 moles) was added and the reaction mixture washeated to 55 to 60° C. for about 5 hr, at which time the deprotectionwas complete. After cooling to about 40 to 45° C., 0.2 g seed crystalsof 8 was added to the reaction mixture resulting in immediatecrystallisation. The slurry was maintained at 40 to 45° C. for about 30minutes and then gradually cooled to 0 to 5° C. After agitating for 2 hrat 0 to 5° C. solids were filtered, washed, with THF (2×50 mL), anddried to give the iosylate salt 8 as a white solid (66 g) with HPLCpurity=99.9%.

The HPLC conditions were as follows; Column; Chiralcel AD—H, SC\523;mobile phase: Heptane; IPA (0.5% TFA)=85:15; flow rate; 1.0 mL/min, andruntime; 20 min.

Compound 8 has the retention time of 12.66 min. Enantiomeric excess ofthis material was greater than 99% ee.

Example 2 Resolution of(±)-3-hydroxy-4-methylamino-pyrrolidine-1-carboxylic Acid, Tert-butylEster, Using Chiral Acids

Resolution of (±)-3-Hydroxy-4-methylamino-pyrrolidine-1 -carboxylicacid, tert-butyl ester was attempted by forming salts with variouschirai acids. Table 3 provides summary of the reactions. In the table,“Compound 4” refers to(±)-3-hydroxy-4-methylamino-pyrrolidine-1-carboxylic acid, tert-butylester. In Table 3, the enantiomeric ratio by chiral HPLC is representedas S:R. In experiment nos. 72, 74 and 75 onwards, HPLC analysis wasperformed at compound 6 stage.

TABLE 3 Study of resolution with various resolving agents: Cmpd 4 ChiralReaction Reaction Input acid temp. time (g)/Eq (g)/Eq (° C.) (hr)Procedure/results Resolution using L-(+)-Tartaric acid 1 0.5 g  0.174 g25-30 Compound 4:L-(+)-Tartaric Acid were used in 2:1 ratio.Crystallization was done in isopropyl alcohol (IPA). Specific OpticalRotation (SOR) of the tartrate complex = +11.024. 2 1.0 g 0.3472 g 25-304 Compound 4:L-(+)-Tartaric Acid were used in 2:1 ratio. Crystallizationwas done in IPA. Yield = 0.4 g, 40.0%; SOR of the tartrate complex =+12.8. The complex was broken to give free amine, which gave SOR of +1.5& Chiral HPLC ratio = 48.73:44.57 (S:R). 3 1.0 g 0.1736 g 55-60 1Compound 4 and L-(+)-Tartaric Acid were used in 1:0.25 ratio. Glacialacetic acid was used as solvent. No crystal formation observed. 4 1.0 g0.1736 g 55-60 1 Compound 4 and L-(+)-Tartaric Acid were used in 1:0.25ratio. Dry MeOH was used for complex formation, & crystallization wascarried out in IPA. White solid (428.0 mg) with SOR = +12.754. 5 1.0 g 0.520 g 55-60 1 Compound 4 and L-(+)-Tartaric Acid were used in1.0:0.75 ratio. MeOH was used for complex formation, & crystallizationattempted in MeOH:IPA mixture (2:4 mL), MeOH:water mixture (4:1 mL),acetone:water (8:2 mL). None of these methods gave crystals. 6 1.0 g0.6944 g 55-60 1 Compound 4 and L-(+)-Tartaric Acid were used in 1:1ratio. No crystal formation. 7 0.5 g L-(+)- 60-65 30.0 min A family ofresolving agents was used. Stoichiometry of Tartaric Compound4:L-(+)-Tartaric Acid:Acetic Acid = 1:0.5:0.5. acid Crystallization wasdone in EtOH + MIBK + acetone (2:10:5 mL). 0.174 g; Complex = 0.34 g.(SOR = + 11.8) & complex was broken, which AcOH was 51.82:48.17enantiomeric ratio (S:R) by chiral HPLC. 0.069 g 8 0.5 g  0.347 g 55-6030.0 min Compound 4 and L-(+)-Tartaric Acid were used in 1:1 ratio.Complex formation was attempted with CuSO₄ in MeOH & crystallization wasattempted in NaOH soln. No crystal formation. Resolution usingD-(−)-Tartaric acid 9 1.0 g  0.347 g 25-30 4 Compound 4 andD-(−)-Tartaric Acid were used in 1:0.5 ratio. MeOH was used for complexformation, and IPA for crystallization. Isolated complex, 850.0 mg. SOR= −11.598. Recrystallization was attempted in ACN + H₂O, acetone + H₂O,ACN + MeOH. No crystal formation. 400.0 mg of crude complex (SOR =−11.598) after crystallization from ACN:IPA mixture gave 130.0 mg ofcrystals with SOR = −10.59 10 1.0 g 0.1735 g 25-30 4 Compound 4 andD-(−)-Tartaric Acid were used in 1:0.25 ratio. MeOH was used for complexformation, and IPA for crystallization. Isolated complex = 420 mg.Recrystallization in IPA gave 180.0 mg of complex with SOR = −12.351.Breaking this complex gave 120.0 mg of solid with SOR = +0.218.Resolution using (+)-Mandelic acid 11 0.5 g  0.350 g 60-65 2 Compound4:(+)-Mandelic acid were used in 1:1 ratio. Complex formation wasattempted in MeOH, & crystallization attempted inMeOH, IPA, and CH₃CN.No crystal formation. 12 0.5 g  0.264 g 55-60 30.0 min Stoichiometry ofCompound 4:(+)-Mandelic Acid = 1:0.75. Complex formation was done inMeOH, & crystallization was done in MIBK. Crystal formation was notobserved. Resolution using (+)-DTTA 13 1.0 g 0.4472 g 55-60 1 Compound4:(+)-DTTA = 1:0.25. EtOH used for complex formation, & IPA forcrystallization. Crystallization inEtOH, EtOH:IPA mixture did notproduce crystals. 14 0.5 g 0.8944 g 55-60 1 Compound 4:(+)-DTTA = 1:1.Isolated complex = 0.665 g. Crystallized from THF:MTBE = 3.0 mL:12 mL.Yield = 0.03586 g; SOR (complex) = +86.40. Enantiomeric ratio (S:R) =46.107:49.715. 15 0.5 g 0.4472 g 55-60 1 Compound 4:(+)-DTTA = 1:0.5.Complex formation in MeOH and crystallization in acetone, IPA, EtOH +MTBE, THF, THF + MTBE mixture. No crystal formation. 16 0.5 g  0.67 g55-60 1 Stoichiometry of Compound 4:(+)-DTTA = 1:0.75. Complex formationwas performed in THF, and crystallization with THF:MTBE = 1:4 gavesticky solid with SOR = +70.057. Resolution using S-(+)-CSA andR-(−)-CSA 17 0.5 g S-(+)-CSA, 55-60 2 Compound 4:S-(+)-CSA = 1:1.Complex formation in acetone and 0.5377 g crystallization in varioussolvents incl. acetone, EtOH + MTBE, acetone + MTBE, ACN. No crystalformation. Sticky mass. 18 0.2 g S-(+)-CSA, 55-60 1 Compound 4:S-(+)-CSA= 1:0.5. Complex formation in MeOH 0.1075 g and crystallization indifferent solvent system did not produce any crystals/solid. 19 0.2 gS-(+)-CSA 55-60 1 Compound 4:S-(+)-CSA = 1:0.75. Complex formation was0.1613 g performed in MeOH. Crystallization did not give anycrystals/solid. 20 0.5 g R-(−)-CSA 55-60 15 min Compound 4:R-(−)-CSA =1:0.5. Complex formation in acetone. 0.1613 g No crystal formation.Resolution using Pyroglutamic Acid and Dibenzoyltartaric acid (DBTA) 210.5 g (+)-DBTA 55-60 30.0 min Stoichiometry of Compound 4:(+)-DBTA =1:0.75. Complex 0.6539 g formation was performed in THF andcrystallization was attempted in various solvents incl. acetone, IPA,EtOH + MTBE, THF, THF + MTBE mixture. Crystal formation not observed. 220.5 g (+)-DTTA 55-60 30.0 min Family of resolving agents was used.Stoichiometry of Compound 0.445 g; 4:DTTA:DBTA = 1:0.5:0.5.Crystallization was done in (+)-DBTA ACN + MTBE (2:12 mL). Yield = 0.5 gwith SOR = +78.126. 0.435 g 23 0.5 g L-(−)-PGA 55-60 30.0 minStoichiometry of Compound 4:L-(−)-PGA = 1:1. Complex 0.298 g formation &crystallization was done in acetone. White solid crystallized out = 0.22 g with SOR = +4.377. Complex was broken to give isomer with SOR =−1.12. HPLC enantiomer ratio (S:R) = 84.037:15.963. 24 0.5 g L-(−)-PGA55-60 30.0 min Stoichiometry Compound 4:L-(−)-PGA = 1:0.75. Complex0.224 g formation & crystallization was done in acetone. White solidcrystallized out = 0. 200 g with SOR = +3.613. Complex was broken togive isomer with SOR = − 1.175. HPLC enantiomeric ratio (S:R) =81.15:16.34. 25 0.5 g L-(−)-PGA 55-60 30.0 min Stoichiometry of Compound4:L-(−)-PGA = 1:0.5. Complex 0.149 g formation & crystallization wasdone in acetone. Yield (Complex) = 0.200 g; SOR = +5.560. Broken isomerSOR = −0.856. 26 1.0 g L-(−)-PGA 55-60 30.0 min Stoichiometry ofCompound 4:L-(−)-PGA = 1:1. Complex 0.597 g formation was done inacetone + MeOH (10 mL + 5 mL) & crystallization in acetone. Complex =0.600 g; SOR = +3.675. Complex was broken to give enantiomer with SOR =+0.210; enantiomers ratio by chiral HPLC as 75:25 (S:R). 27 1.0 gL-(−)-PGA 55-60 30.0 min Stoichiometry of Compound 4:L-(−)-PGA = 1:1.Complex 0.597 g formation was done in ACN + H₂O & crystallization inACN. Complex = 0.460 g ; SOR = +5.560. Complex was broken to give isomerwith SOR = − 1.191. HPLC enantiomers = 77.202:22.798 (S:R). 28 0.5 gL-(−)-PGA, 80-90 30.0 min Stoichiometry of Compound 4:L-(−)-PGA = 1:1.Complex 0.299 g formation was done in t-BuOH. No crystal formation. 291.0 g L-(−)-PGA, 80-90 30.0 min Stoichiometry of Compound 4:L-(−)-PGA =1:1. Complex 0.597 g formation in n-Pentanol gave 0.6 g with SOR = 2.98;Complex was broken to give 0.45 g of enantiomer, SOR = −1.93 andenantiomeric ratio by HPLC = 70.795:29.20 (S:R). 30 3.0 g L-(−)-PGA55-60 30.0 min Stoichiometry of Compound 4:L-(−)-PGA = 1:1.Recrystallization 1.79 g was done in acetone:MeOH mixture. Three cropswere obtained. 1^(st) crop 920.0 mg with enantiomeric ratio 78.8:20.96(S:R)and SOR = −0.297; 2^(nd) crop = 1100 mg with enantiomeric ratio95.49:4.5 (S:R) and SOR = −1.874; 3^(rd) crop = 700 mg with enantiomericratio 0:100 (S:R)and SOR = +0.900. 31 1.0 g L-(−)-PGA 55-60 30 minStoichiometry of Compound 4:L-(−)-PGA = 1:1. Recrystallization 0.597 gwas done in THF. Complex (0.5 g) was broken to give enantiomer with HPLCratio 63.2:36.8 (S:R)& SOR = +0.218. 32 1.0 g L-(−)-PGA 55-60 1.0Stoichiometry of Compound 4:L-(−)-PGA = 1:1. Recrystallization 0.597 gin IPA:MIBK (10:5 mL) gave 0.4 g complex. The complex was broken to giveenantiomer with HPLC ratio 74.71:25.29 (S:R) and SOR = −0.307. 33 0.5 gL-(−)-PGA 55-60 1.0 Stoichiometry of Compound 4:L-(−)-PGA = 1:1.Recrystallization 0.2986 g in IPA:MEK (4:8 mL) gave 0.26 g complex.Complex was broken to give enantiomer with HPLC ratio 80.71:19.28 (S:R);SOR = −2.198. 34 0.5 g L (−)-PGA 60-65 1.0 Compound4:L-(−)-PGA:L-Proline = 1:0.5:0.5. Recrystallization 0.1495 g; wasattempted in MeOH, but no crystal formation was observed. L-Proline,0.13 g 35 1.0 g L (−)-PGA 40-45 1.0 Compound 4:L-(−)-PGA:Propionic Acid= 1:0.5:0.5. Complex 0.298 g; formation & crystallization was done inacetone. Complex = 0.43 g Propionic and complex was treated with aq.K₂CO₃ to give enantiomer Acid, (0.258 g) with SOR = −1.274. HPLC ratio81.36:18.63 (S:R). 0.171 g 36 1.0 g L-(−)-PGA 40-45 1.0 Stoichiometry ofCompound 4:L-(−)-PGA:Propionic Acid = 0.298 g; 1:0.5:0.5. Complexformation & crystallization was done in Propionic acetone. White solidppt out = 0.401 g and complex was broken Acid using K₂CO₃ to give isomer(0.238 g) with SOR = +0.098. HPLC 0.171 g ratio 82.16:17.84 (S:R). 371.0 g L-(−)-PGA 85-90 1.0 n-Pentanol used as solvent for complexformation and 0.2986 g recrystallization. Compound 4:L-(−)-PGA = 1:0.5.Crystallization was achieved with mixture of n-Pentanol and MIBK.Pentanol alone doesn't yield any crystallization. SOR = +1.022. HPLCratio 75.36:24.63 (S:R). 38 1.0 g L-(−)-PGA 85-90 1.0 2-Propanol used assolvent for complex formation and 0.2986 g recrystallization. No crystalformation observed. 39 1.0 g L-(−)-PGA 40-50 1.0 Stoichiometry ofCompound 4:L-(−)-PGA = 1:0.6. Acetone:water 0.358 g (12:0.4 mL) mixturewas used for complex formation and recrystallization with acetone:water(10:0.4 mL). SOR of the enantiomer = −0.89. Purity by HPLC = 98.70%. 4010.0 g  L-(−)-PGA 85-90 1.0 Stoichiometry of Compound 4:L-(−)-PGA =1:0.9. Methyl ethyl 5.37 g ketone:IPA (100:40 mL) mixture used forcomplex formation (6.7 g) and IPA:MEK (30:45 mL) mixture used forrecrystallization: complex = 4.3 g, Chiral HPLC S:R = 91.74:8.26. Thecomplex was 2^(nd) recrystallized gave 3.0 g of the complex. Chiral HPLCS:R = 95.4:4.6. 41 10.0 g  L-(−)-PGA 40-50 1.0 Stoichiometry of Compound4:L-(−)-PGA = 1:0.6. Acetone:water 3.58 g (120:4 mL) mixture was usedfor complex formation and crystallization (5.7 g). Recrystallizationwith acetone:water gave 4.2 g (Chiral HPLC S:R = 93.6:6.4). 2^(nd) timerecrystallization with acetone:water mixture gave 2.3 g of complex(Chiral HPLC S:R = 100:0). 42 1.0 g L-(−)-PGA 85-90 1.0n-Pentanol:Acetone (15:5 mL) mixture was used for complex 0.2986 gformation. Stoichiometry of Compound 4:L-(−)-PGA = 1:0.5. Nocrystallization. 43 1.0 g L-(−)-PGA 50-55 1.0 Compound 4:L-(−)-PGA =1:0.5. IPA:acetone (2:13 mL) mixture 0.2986 g was used for complexformation (0.411 g) by stirring at RT for 2 h and cooled to 0-10° C. andthe complex was broken to give enantiomer (0.1886 g, Chiral HPLC S:R =79:18) with SOR = −1.0. 44 1.0 g L-(−)-PGA 50-55 1.0 Compound4:L-(−)-PGA = 1:1. IPA:acetone (2:13 mL) mixture 0.597 g was used forcomplex formation (0.7496 g) and the complex (SOR = 3.968) was broken togive enantiomer (0.386 g) with SOR = −0.959, Chiral HPLC S:R =80.58:19.29. 45 1.0 g L-(−)-PGA 50-55 1.0 Compound 4:L-(−)-PGA = 1:1.IPA:Acetone (2:13 mL) mixture 0.2986 g was used for complex formation(0.471 g) by stirring at RT overnight and cooled to 0-10° C. and thecomplex was broken to give enantiomer (0.2711 g, Chiral HPLC S:R =89.98:10.02) with SOR = −0.689. 46 10.0 g  L-(−)-PGA 40-50 1.0 Compound4:L-(−)-PGA = 1:1. Acetone:MeOH (130:10 mL) mix 5.98 g was used forcomplex formation and crystallization gave 7.6 g (Chiral HPLC S:R =83.3:16.7). Recrystallized with acetone:MeOH:water mix gave 3.9 g(Chiral HPLC S:R = 88.69:11.3). 47 10.0 g  L-(−)-PGA 40-50 1.0 Compound4:L-(−)-PGA = 1:0.5. Acetone:water (80:2.5 mL) mix 3.0 g used forcomplex formation & crystallization gave 4.8 g (S:R = 78.23:21.77). Thenit was recrystallized with acetone:water mixture gave 3.4 g. Chiral HPLCS:R = 86.98:13.02. 48 10.0 g  L-(−)-PGA 40-50 1.0 Stoichiometry ofCompound 4:L-(−)-PGA = 1:0.59. 3.5 g Acetone:MeOH (80:5 mL) mixture wasused for complex formation and crystallization gave 6.0 g Chiral HPLCS:R = 79.78:20.21. 49 10.0 g  L-(−)-PGA 50-60 1.0 Compound 4:L-(−)-PGA =1:1. IPA used for complex formation 5.97 g and (IPA:acetone = 1:5) mixused for crystallization (11.0 g). Broken complex (3.71 g); enantiomer(S:R = 68.2:31.7). 50 20.0 g  L-(−)-PGA 50-60 1.0 Compound 4:L-(−)-PGA =1:1. Acetone used for complex 11.94 g formation and crystallization(15.1 g) and the complex was broken to give the 8.65 g of enantiomer.Chiral enantiomeric S:R = 76.77:23.23. MLR was concentrated, Wt = 9.0 g,Chiral HPLC Compound 6 S:R = 26.84:73.16. 51 2.0 g L-(−)-PGA 50-60 1.0Compound 4:L-(−)-PGA:Conc. HCl = 1:0.5:0.5. Acetone (20 mL) 0.6069 g wasused for complex formation and crystallization (44.0 mg). 52 2.0 gL-(−)-PGA 50-60 1.0 This is a second resolution of enantiomer (S:R =71.0:29.0) obtained 0.717 g in Experiment 70 below. Compound 4:L-(−)-PGA= 1:0.6. Acetone:water (24:0.8 mL) was used for complex formation andcrystallization (2.56 g). The complex was broken to give 1.7 g ofenantiomer. Analysis by chiral HPLC (S:R = 96.5:3.2).. Resolution usingProline and Lactic Acid 53 0.5 g L-Proline 60-65 1.0 Compound4:L-Proline = 1:1. Recrystallization in MeOH gave 0.2665 g 0.07 g ofcomplex with SOR = −86.046. 54 2.0 g L-Proline 60-65 1.0 Compound4:L-Proline = 1:1. Recrystallization in MeOH gave 1.066 g 0.98 g; SOR =−84.93. 55 0.5 g Boc-L-Proline 45-50 1.0/O.N Compound 4:Boc-L-Proline =1:1. Acetone was used for complex 0.5 g formation and crystallization.Crystallization not observed. 56 0.5 g Boc-L-Proline 55-60 1.0 RT-O.NCompound 4:Boc-L-Proline = 1:1. MeOH used for complex 0.5 g formationand crystallization. Crystallization not observed. 57 0.5 gBoc-L-Proline 75-80 1.0 RT-O.N Compound 4:Boc-L-Proline = 1:1. IPA usedfor complex 0.5 g formation and crystallization. Crystallization notobserved. 58  0.5 g, L(+)-Lactic 50-55 1 Compound 4:L-Lactic Acid = 1:1.Various solvents incl. acetone, Acid 0.2 g MeOH, MDC and IPA attempted.Crystallization not observed. Resolution using Malic acid 59 0.5 gD-(+)- 50-55 1.0 Compound 4:D-(+)-Malic Acid = 1:1. Complex (0.58 g)formation Malic Acid done in acetone (10.0 mL) and Isomer = 0.335 g withSOR = +0.851 0.3103 g and chiral HPLC ratio of S:R = 16.56:83.4. 60 1.0g D-(+)- 50-55 1.0 Compound 4:D-(+)-Malic Acid = 1:0.25. Acetone:water(12:0.4) Malic Acid mix for complex formation and crystallization gave0.54 g and 0.155 g recrystallization with acetone:water gave 0.24 g withchiral HPLC S:R = 54.74:45.26. 61 1.0 g D-(+)- 50-55 1.0 Stoichiometryof Compound 4:D-(+)-Malic Acid = 1:0.5. Malic Acid Acetone:IPA mixtureused for complex formation and 0.31 g crystallization gave 0.75 g andchiral HPLC S:R = 53.0:47.0). 62 0.5 g D-(+)- 45-50 1.0 Compound4:D-(+)-Malic Acid = 1:0.25. Acetone used for Malic Acid complexformation and crystallization gave 0.231 g and the 0.774 g complex wasbroken with aq. K₂CO₃ to give 0.1886 g of enantiomer with SOR = +1.637and chiral HPLC S:R = 51.66:48.3). 63 0.5 g D-(+)- 45-50 1.0 Compound4:D-(+)-Malic Acid = 1:0.5. Acetone used for complex Malic Acidformation and crystallization gave 0.5365 g, and the complex was 0.155 gbroken with aq. K₂CO₃ to give 0.2986 g of enantiomer with SOR = −2.231;chiral HPLC S:R = 45.93:54.07. 64 1.0 g D-(+)- 45-50 1.0 Compound4:D-(+)-Malic Acid = 1:0.25. IPA used for complex Malic Acid formationand crystallization gave 0.450 g and 50.0 mg of the 0.155 g complex wasbroken with aq. K₂CO₃ to give enantiomer with chiral HPLC S:R =52.49:47.5. 65 0.5 g L-(−)- 50-55 1 h Compound 4:L-(−)-Malic Acid = 1:1.Acetone was used. Complex = Malic Acid 0.312 g & complex was broken withaq. K₂CO₃ to give 0.31 g enantiomer (0.1825 g). Chiral HPLC S:R =83.6:13.7. 66 5.0 g L-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1.Acetone was used. Complex = Malic Acid 3.51 g and the complex was brokenwith aq. K₂CO₃ to give 3.103 g enantiomer (1.725 g). Chiral HPLC S:R =81.3:18.7 67 2.0 g L-(−)- 60-70 1.0 Compound 4:L-(−)-Malic Acid = 1:1.IPA was used for complex Malic Acid formation and crystallization.Crystallization not observed. 1.24 g 68 2.0 g L-(−)- 50-60 1.0 Compound4:L-(−)-Malic Acid = 1:1. IPA used for complex Malic Acid formation &IPA:acetone mix used for crystallization (1.188 g). 1.24 g Complex wasbroken, gave 0.5639 g of enantiomer. Chiral HPLC = 100.00%. 69 Complex L(−)- 50-60 1.0 This is a second resolution of enantiomer (S:R =26.84:73.16) 2.0 g Malic Acid obtained in Experiment 50 above. 2.0 g ofmalic acid complex (S:R = 1.24 g (S:R = 76.77:23.2) was taken forfurther resolution with L-(−)-malic 76.77:23.2) acid. Stoichiometry ofCompound 4:L-(−)-Malic Acid = 1:1. 10 V (20.0 mL) of acetone:IPA mixused for complex formation and crystallization (1.6 g). Enantiomer (1.15g, S:R = 99.4:0.3) was obtained after breaking the complex. 70 20.0 g L-(−)- 50-60 1.0 Compound 4:L-(−)-Malic Acid = 1:1. 4 V (80.0 mL) ofMalic Acid acetone:IPA mix used for complex formation andcrystallization 11.95 g (15.5 g) and the complex was broken to give 8.60g of enantiomer. Chiral HPLC S:R = 71.0:29.0. 71 3.3 g D-(+)- 50-60 1.0This is a second resolution of enantiomer (S:R = 26.84:73.16) Malic Acidobtained in Experiment 50 above. Compound 4:D-(+)-Malic Acid = 2.0 g1:1. Acetone (50.0 mL) used for complex formation & crystallization (3.5g). Complex was broken to give 2.0 g of enantiomer. Chiral HPLC S:R =0.81:99.19. 72 3.0 g L-(−)- 50-60 1.0 Compound 4:L-(−)-Malic Acid = 1:1.Acetone:water (30:1 mL) Malic Acid was used for complex formation andcrystallization (1.6 g). Chiral 1.86 g HPLC (Compound 6) S:R = 97.0:3.0.73 10.0 g  L-(−)- 50-60 1.0 Compound 4:L-(−)-Malic Acid = 1:1.Acetone:water (70:2 mL) Malic Acid mix was used for complex formationand crystallization (5.6 g). 6.2 g Chiral HPLC analysis Compound 6 (S:R= 100:0). MLR was concentrated, Wt = 10.5 g. Chiral HPLC S:R =18.2:81.8). 74 10.0 g  L-(−)- 50-60 1.0 Compound 4:L(−)-Malic Acid =1:1. Acetone:water (60:2 mL) mix Malic Acid was used for complexformation and crystallization (5.5 g). Chiral 6.2 g HPLC Compound 6 S:R= 100:0. 75 1.47 g  L-(−)-PGA 50-55 1.0 Compound 4:L-(−)-PGA:L-(−)-MalicAcid = 1:0.5:0.5. Acetone 0.44 g; (10.0 mL) was used as solvent. Complex= 300 mg. Chiral HPLC L-(−)- Compound 6 S:R = 87.17:12.83. Malic Acid,0.45 g 76 1.0 g L-(−)- 40-45 1.0 Compound 4:L-(−)-Malic Acid:Acetic Acid= 1:0.5:0.5. Complex Malic acid formation & crystallization was done inacetone (7.0 mL). Solid 0.31 g; ppt out = 0.35 g. Chiral HPLC S:R =100.0:0.0. AcOH, 0.14 g 77 5.0 g L-(−)- 50-55 1 Stoichiometry ofCompound 4:L-(−)-Malic Acid = 1:1. Malic Acid Acetone:water (30:0.5 mL)was used. Minimum amt of water used 3.10 g to check the change in yieldand purity. Filtration of crystals at 20- 25° C. Complex = 3.1 g. ChiralHPLC S:R = 100.0:0. 78 5.0 g L-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid= 1:1. Acetone:water (30:0.5 mL). Malic Acid Minimum amt water used tocheck change in yield & purity. 3.10 g. Filtration at 0-5° C. Complex =3.2 g. Chiral HPLC S:R = 99.20:0.80. 79 2.0 g L-(−)- 50-55 1 Compound4:L-(−)-Malic Acid = 1:1. Acetone:MeOH (10:3 mL) Malic Acid was used assolvent. Complex = 0.90 g. Chiral HPLC S:R = 1.2416 g. 100.0:0. 80 3.0 gL-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:MeOH (10:3 mL)Malic acid was used. Complex = 1.1437 g. 1.864 g 81 100 g  L-(−)- 50-551 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (600:18 mL) Malicacid used. Complex = 57.0 g. Chiral HPLC S:R = 100.0:0. 62.0 g 82 1.04g  L-(−)- 50-55 1 Crude Compound 4 was used. Stoichiometry of Compound4:L- Malic acid (−)-Malic Acid = 1:1. Acetone:water (6:0.1 mL) mix wasused. 0.64 g Complex = 0.5 g. Chiral HPLC S:R = 99.2:0.8. 83 1.8 gL-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (12:0.2mL) Malic acid used. Complex = 1.0 g. Chiral HPLC S:R = 100.0:0.0. Note:Crude 1.1 g epoxide & crude Compound 4 were used. 84 1.2 g L-(−)- 50-551 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (10:0.2 mL) Malicacid used. Complex = 0.82 g. Chiral HPLC S:R = 100.0:0.0. 0.73 g. Note:Crude epoxide & crystallized Compound 4 were used. 85 100 g  L-(−)-50-55 1 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (600:13 mL)Malic acid used. Complex = 60.0 g. Chiral HPLC S:R = 100.0:0. Min. amtof 62.0 g water used for crystallization. 86 2.0 g L-(−)- 50-55 1 CrudeCompound 4 obtained from direct synthesis through Malic acid bromohydrinwas used. Stoichiometry of Compound 4:L-(−)-Malic 1.2 g Acid = 1:1.Acetone:water (15:0.2 mL) mix was used. No crystallization observed. 878.0 g L-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water(40:0.5 mL) 80.0% Malic Acid was used. Complex = 3.6 g. Chiral HPLC S:R= 98.04:1.96. purity 4.0 g Compound 4 directly prepared from bromohydrinwas used. Malic acid quantity used was based on purity of the crudeCompound 4. 88 58.0 g L-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1.Acetone:water (360:5 mL) 84.3% Malic Acid was used. Complex = 32.0 g.Chiral HPLC S:R = 99.4:0.6. purity 36.0 g Compound 4 directly preparedfrom crude epoxide was used. 89 40.0 g L-(−)- 50-55 1 Compound4:L-(−)-Malic Acid = 1:1. Acetone:water (240:4 mL) 79% Malic Acid wasused. Complex = 20.0 g. Chiral HPLC S:R = 94.9:5.1. purity 24.8 gCompound 4 directly prepared from bromohydrin was used. Malic acidquantity was used based on weight of the crude Compound 4. 90 53.0 g L-(−)- 50-55 1 Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (300:5mL) Malic Acid was used. Complex = 30.2 g. Chiral HPLC S:R = 95.1:4.9.Malic 32.8 g acid quantity was used based on weight of the crudeCompound 4. Moisture content by Kf = 1.7% 91 10.0 g  L-(−)- 50-55 1Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (60:1 mL) Malic Acidwas used. Complex = 9.0 g. Chiral HPLC S:R = 65.6:34.4. 6.2 g AqueousCompound 4 solution (40%, 0.25 mL) was deliberately added to thereaction mass to understand the effect of free Compound 4. Yellow stickymass (complex). NMR showed impurity peak. 92 5.0 g L-(−)- 50-55 1Compound 4:L-(−)-Malic Acid = 1:1. Acetone:water (30:0.6 mL) Malic Acidwas used. Complex = 4.0 g. Chiral HPLC S:R = 70.7:29.3. 0.5% 3.1 g FreeCompound 4 (0.06 mL 40% aq. soln) was added to the reaction mass.Complex becomes slightly sticky (yellow). 93 10.0 g  L-(−)- 50-55 1Compound 4:L(−)-Malic Acid = 1:1. Acetone:water (60:1 mL) was Malic Acidused. Complex = 5.8 g. Chiral HPLC S:R = 98.6:1.4. Free 6.2 g Compound 4was not added to the reaction mass. Complex obtained as white, freeflowing solid.

As seen from the data, resolution of(±)-3-hydroxy-4-methylamino-pyrrolidine-1-carboxybc acid, tert-butylester with L-(−)-malic acid (1:1) produces S enantiomer in up to 100%enantiomeric excess.

Example 3 Large Scale Preparation for SNS-595

Synthesis of Compound 8

N-Boc-3-pyrroline (1) (16 kg) was treated with1,3-dibromo-5,5-dimethylhydantoin (DBDMH) (15.2 kg) in aqueous ACN toform the bromohydrin (2). After the reaction was complete, the excessbrominating agent was quenched with aqueous sodium thiosulfate solutionand the crude reaction mixture was treated with aqueous NaOH. Theresulting epoxide was extracted with MTBE and the organic layer wasconcentrated to give the crude epoxide (3). This epoxide was added to40% aqueous raethytamine and, after the reaction was complete, theexcess methylamine and water were removed by distillation and theproduct, (4), (18.5 kg) was isolated from diisopropyl ether.

Racemic compound 4 (18.4 kg) was resolved by treatment with L-(−)-malicacid (11.4 kg) in aqueous acetone. The (S,S)-isomer (5) crystallized asthe L-(−)-malate salt (5A). This was filtered and the filter cake waswashed with acetone and dried to give compound 5A (11.8 kg).

A slurry of compound 5A (11.8 kg) and potassium carbonate (11.7 kg) inmethanol was treated with Boc-anhydride (Boc₂O) (8.3 kg) until thereaction was complete. The product was extracted with MTBE. The organiclayer was dried by distillation and petroleum ether added. The slurrywas filtered, washed with petroleum ether and dried to give compound 6(9.9 kg).

Compound 6 (9.9 kg) was treated with a solution of KHMDS (35 kg, 20%w/w) in THF, followed by dimethyl sulfate (4.7 kg). After completion ofthe reaction, the reaction mixture was quenched with 5% acetic acid inwater. The product was extracted with MTBE, and the organic layerconcentrated to give crude product (7). This was treated with p-toluenesulfonic acid monohydrate (TsOH) in a tettuhydrofuran-methanol mixture.After completion of the reaction, the slurry was cooled and the productis isolated by filtration to give 12.2 kg of Compound 8.

Synthesis of Command 10

A solution of earbonyidiimidazole (CDl) (16.4 kg) in THF was added to aslurry of 2,6-dichloronicotinic acid (9) (16 kg) in THF. After about 2hr, ethyl potassium malonate (EtO₂CCH₂CO₂K) (19.4 kg), triethylamine(25.9 kg) and magnesium chloride (11.9 kg) were added and the reactionstirred for about 24 hr. The reaction mixture was quenched with diluteHCl and extracted with ethyl acetate. The organic layer wasconcentrated, washed with a mixture of aqueous NaCl and NaHCO₃. Theorganic layer was diluted with methylcyclohexane and dried by vacuumdistillation. The solution was treated with triethylorthoformate (17.1kg) and acetic anhydride (59 kg) at about 90 to 110° C. After thereaction was judged to be complete, the excess acetic anhydride wasremoved by distillations with methylcyclohexane. The crude product wastreated with a solution, of 2-aminothiazole (8.2 kg) in THF. After about2 hr, the reaction mixture was treated with potassium carbonate (13.6kg) and the mixture stirred for about 6 hr. The product was precipitatedby the addition of water, isolated by filtration, washed with ACN-water,ACN, and dried so give compound 10 (13.1 kg).

Synthesis of SNS-595

To a slurry of Compound 8 (8.0 kg) in ACN at about 5° C.,N,N′-diisopropylethylamine (EtN¹Pr₂) (8.7 kg) was added. After about 15min, Compound 10 (5.0 kg) was added to the reaction mixture. Thereaction mixture was heated to about 45° C. for about 3 hr, cooled andthe product filtered. The filter cake was washed with ACN and dried togive Compound 11 (5.5 kg).

To a solution of NaOH (0.8 kg) in water (19.5 kg). Compound 10 (5.5 kg)and ethanol (EtOH, 0.5 kg) were added. After hydrolysis was complete,the reaction mixture was filtered and the filtrate acidified, to pH 73to 7.7 by the addition of acetic acid. The mixture was then heated toabout 55 to 65° C. for about 2 hr. After cooling to ambient temperature,the reaction mixture was filtered and washed with water and then withethyl alcohol. The filter cake was dried, under vacuum. The crudeproduct was slurried in EtOH at about 80° C. After cooling, the productwas filtered, washed with EtOH and dried to give SNS-595 (3.8 kg).Weight percent purity of SNS-595 was determined to be 99.9%,

EXAMPLE 4 Pharmaceutical Composition Suitable for Injection orIntravenous Infusion

An illustrative example of a suitable pharmaceutical compositioncomprises: 10 mg of SNS-595 and(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid (wherein the amount of SNS-595 is at least 99.95% and the amount of(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthrydine-3-carboxylicacid is less than about 0.95%) per milliliter (mL) of an aqueous 4.5%solution of sorbitol, that is adjusted to pH 2.5 with methanesulfonicacid. One protocol for making such a solution includes the following formaking a 100 mg/10 mL presentation: 100 mg of an active composition,which consists essentially of at least 99.95% SNS-595 and less than0.05%(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid, and 450 mg D-sorbitol are added to distilled water; the volume isbrought up to a volume of 10 mL; and the resulting solution is adjustedto pH 2.5 with methauesuifonic acid. The resulting composition is alsosuitable for lyophilization. The lyophilized form is then reconstitutedwith sterile water to the appropriate concentration prior to use.

EXAMPLE 5 Pharmaceutical Composition Suitable for Injection orIntravenous Infusion

An illustrative example of a suitable pharmaceutical compositioncomprises: 10 mg of total of SNS-595 and impurities (wherein the amountof SNS-595 is ar least about 99.95% and the total amount of impurity isless than about 0.05%) per mL of aqueous solution of 4.5% sorbitol thatis adjusted to pH 2.5 with methanesulfonic acid. One protocol for makingsuch a solution includes the following for making a 100 mg/10 mLpresentation 100 mg composition consisting essentially of at least about99.95% SNS-595 and less than about 0.05% impurities and 450 mgD-sorbitol are added to distilled water; the volume is brought up to avolume of 10 mL; and the pH of the resulting solution is adjusted to 2.5with methanesolfonic acid. The resulting composition is also suitablefor lyophilization. The lyophillized form is then reconstituted withsterile water to the appropriate concentration prior to use.

The embodiments of the claimed subject matter described above areintended to be merely exemplary, and those skilled in the art willrecognise, or will be able to ascertain using no more than routineexperimentation, numerous equivalents of specific compounds, materials,and procedures. All such equivalents are considered to be within thescope of the claimed subject matter and are encompassed by the appendedclaims.

1-44. (canceled)
 45. A single unit dosage form comprising a compositionconsisting essentially of at least 99.95%(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid and less than 0.05%(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-amino-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid based on total weight of the composition.
 46. The single unitdosage form of claim 45, wherein the composition is a lyophilizedpowder.
 47. The single unit dosage form of claim 45 comprisingsufficient(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid to permit administration of doses of(+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylicacid within the range of about 10-100 mg/m².
 48. The single unit dosageform of claim 45, wherein the dosage form is for intravenousadministration.
 49. The single unit dosage form of claim 45 comprisingabout 1-50 mg of the composition.
 50. The single unit dosage form ofclaim 49 comprising about 25 mg of the composition.
 51. The single unitdosage form of claim 49 further comprising methanesulfonic acid.
 52. Thesingle unit dosage form of claim 51 further comprising sorbitol.
 53. Thesingle unit dosage form of claim 51 suitable for reconstitution withwater to provide a liquid dosage form for intravenous administration.